Electronically assisted chemical stimulus for symptom intervention

ABSTRACT

A symptom intervention system monitors data representative of a user&#39;s movement, identifies an onset of a symptom of a physical condition, and applies an actuation to intervene with the identified onset. A machine-learned model is trained to identify an onset of a symptom based on the monitored data . The system may use the machine-learned model to determine whether to modify an upcoming administration of a chemical stimulus that is administered to the user to treat their physical condition. The system may determine a modification to a dose or a time associated with the upcoming administration of the stimulus and apply the stimulus to the user based on the determined modification. The system may use the machine-learned model to determine that the user is exhibiting a particular symptom of their physical condition. Depending on the symptom, the system may depolarize or hyperpolarize neurons of the user.

CROSS REFERENCE To RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No.63/071,376, filed Aug. 28, 2020, which is incorporated by reference inits entirety.

TECHNICAL FIELD

This disclosure relates generally to a symptom intervention system, andmore specifically to monitoring of activity of a user (e.g., motoractivity) and optimizing symptom intervention based on the monitoredactivity.

BACKGROUND

Conditions such as cerebral palsy, multiple sclerosis, and Parkinson'sdisease have undesired effects on motor function and are yet to becurable. For example, Parkinson's disease (PD) is the second most commonneurodegenerative disorder, affecting 10 million people worldwide.Characterized by tremor, muscular rigidity, and decreased mobility, PDhas a staggering effect on quality of life and leaves many patientsunable to walk or feed themselves. The economic burden of PD is alsosignificant, reaching over $25 billion in direct medical costs ($50billion total) in the United States. While the neurobiology ofParkinson's disease and its characteristic loss of dopamine-producingneurons is well described, the disease remains incurable. Existingtreatments to conditions such as PD fail to stop disease progression,are challenging to titrate, and have themselves several undesirablemotor side effects.

Chemical stimuli can help care for patients with such conditions. Forexample, oral administration of levodopa (1-DOPA) is one manner of carefor PD. As a precursor to dopamine, 1-DOPA reverses the chemicalimbalance caused by Parkinson's and, in turn, restores normal motorfunction. However, achieving its proper dosage remains a majorchallenge. When 1-DOPA levels in the bloodstream become low, symptoms ofmotor dysfunction can return without notice (“off” periods). Conversely,high levels can lead to visual hallucinations and involuntary movements.This titration becomes further complicated as the disease progresses andmore neurons in the brain die. The general unpredictability of apatient's symptoms over the course of a day can lead to secondary issuessuch as anxiety, depression, and isolation that results from avoidingsocial interactions.

Although these conditions can be marked by a handful of hallmarkcharacteristics, each are highly variable and no two patients having thesame condition will exhibit the same combination or degree of symptoms.Clinicians therefore rely on standardized rating scales to assess apatient's condition, track disease progression, and evaluateresponsiveness to treatment. For example, the motor section of theUnified Parkinson's Disease Rating Scale (UPDRS), which is the goldstandard for assessing a PD patient's motor symptoms, requires thepatient to perform a series of motor tasks, which are visually evaluatedby trained personnel. Unfortunately, these rating scales are limited bypoor temporal resolution and the subjective nature of scoring. Becausesymptom severity fluctuates through the day and can worsen withmultitasking, clinical exams are also unlikely to capture the real-worldseverity of a patient's disease.

SUMMARY

The symptom intervention methods and systems described herein implementsmachine learning and control mechanisms to personalize and optimize auser's management of physical condition symptoms. A symptom interventionassembly addresses the challenges with chemical stimuli titration inmanaging the symptoms of physical conditions by supplementing thechemical stimuli with a device-led combination therapy that increasesthe precision in which the stimuli is titrated and helps restore apatient's ability to perform otherwise difficult activities. Theassembly can perform closed-loop monitoring and augmentation of motoractivity. On-body sensors provide continuous measurements of symptomstate and applies an actuation that intervenes with symptoms of aphysical condition. For example, the assembly can stimulate theneuromuscular system to directly augment movements and improve mobilitythrough neuromodulation or functional electrical stimulation (FES).

The symptom intervention assembly described herein determines anactuation to intervene with an onset of a physical condition's symptomusing a machine-learned model that identifies the onset of the symptombased on monitored activity data such as muscle kinematics, muscleelectroactivity, hormone levels, and chemical stimuli intake. Themachine-learned model can be trained on generalized activity datacollected across a population of users or on data associated with aparticular user's activity, which fine tunes its symptom onsetidentification for that user and enables personalized symptomintervention. The assembly uses the identified onset to determine anactuation instruction for intervening with the symptom. The actuationinstruction can also be personalized to a user.

After the symptom intervention assembly applies an actuationinstruction, the assembly can monitor the user's movement to gauge alevel of efficacy of the applied actuation in intervening with theidentified symptom onset. By comparing the monitored movement to atarget movement (e.g., a neurotypical gait or stillness of a hand thatis not experiencing a tremor), the system can re-train themachine-learned model and further personalize the actuation to the user.

In one embodiment, a symptom intervention system identifies a chemicalstimulus administered to a user to treat a physical condition of a user.An upcoming administration of the chemical stimulus is characterized byat least one of a dose and a time to administer the chemical stimulus.

The system monitors movement signals representative of movement of theuser. For example, the system monitors inertial measurement unit (IMU)signals taken as the user is walking. The system determines, using amachine-learned model configured to identify an onset of a symptom ofthe physical condition based on the monitored movement signals, whetherto modify the upcoming administration of the chemical stimulus. Themonitored signals may, for example, show that the user is experiencing aslowing or shuffling gait. In response to determining to modify theupcoming administration of the chemical stimulus, the system determinesa modification to the dose or the time associated with the upcomingadministration of the chemical stimulus and applies the chemicalstimulus to the user based on the determined modification. For example,the system may administer an increased dose of levodopa to the user oradminister the upcoming dose of levodopa earlier than scheduled.

The symptom intervention system can train the machine-learned modelusing historical activity data, which can be collected across apopulation of users. The system can receive historical activity datacollected from sensors configured to monitor a given user's activitydata, where the historical activity data includes at least one ofhistorical movement signals, hormone activity, a previous administrationof the chemical stimulus, a heart rate, or a respiration rate. Thesystem labels the historical activity data with a given symptom labelrepresentative of a corresponding symptom characterized by thehistorical activity data, creates a first training set based on thelabeled historical activity data, and trains the machine-learned modelusing the first training set.

The system can label the monitored movement signals with a symptom labelrepresentative of the symptom characterized by the monitored movementsignals, create a second training set using the labeled movementsignals, and retrain the machine-learned model using the second trainingset such that the machine-learned model is customized to the motions ofthe user. The system can also receive feedback of the determinedmodification indicating a measure of approval that the user has with thedetermined modification, modify an association between the identifiedonset of the symptom of the physical condition and the monitoredmovement signals, and retrain the machine-learned model using themodified association.

Hormone activity of the user can be monitored by the system usingsensors configured to measure at least one of a level of a hormone or alevel of a biomolecule regulated by the hormone. The machine-learnedmodel may be configured to identify the onset of the symptom of thephysical condition further based on the monitored hormone activity. Thesystem can determine whether to modify the upcoming administration ofthe chemical stimulus by generating a feature vector representative ofthe monitored movement signals and one or more of a hormone activity ofthe user, a previous administration of the chemical stimulus, and motorintent data of the user. The machine-learned model can be applied to thefeature vector, where the machine-learned model identifies the onset ofthe symptom with a confidence score as being associated with the featurevector. In response to the confidence score exceeding a thresholdconfidence, the system can determine to modify the upcomingadministration of the chemical stimulus.

In some embodiments, the system may determine an “on” time duration of aprevious administration of the chemical stimulus. The “on” time durationcan start at a first time to administer the chemical stimulus and end atan occurrence of the symptom after the first time to administer thechemical stimulus. The system can identify the first occurrence of thesymptom using the machine-learned model. The system may also determinean “off” time duration of the previous administration of the chemicalstimulus. The “off” time duration can start at the first occurrence ofthe symptom and end at a second time to administer the chemical stimulusafter the first time. The system can determine whether to modify theupcoming administration of the chemical stimulus by determining if the“off” time duration is greater than the “on” time duration and, if so,determine to modify the upcoming administration.

The system can cause a client device to render a graphical userinterface (GUI) including user input fields to approve or reject thedetermined modification. In response to receiving a user inputindicating that the determined modification is approved, the system canmodify the dose or the time associated with the upcoming administrationof the chemical stimulus. Similarly, the system can cause a clientdevice to render a GUI including a user input field to stop aneuromodulation of the first group of neurons. In response to receivinga user input at the user input field, the system may modify anassociation between the identified onset of the symptom of the physicalcondition and the monitored plurality of movement signals. The systemcan retrain the machine-learned model using the modified association.

In some embodiments, the system can determine kinematic metric scores toidentify the symptom onset. The system measures movement signals at twojoints of the user, where the two joints are symmetric to one anotherabout the sagittal plane. The system can determine a first kinematicmetric score based on a comparison of the movement signals of one jointto the movement signals of the other, where the first kinematic metricscore indicates a measure of symmetry of motion about the sagittalplane. A baseline movement profile of one joint can be generated by thesystem using historical movement signals collected at that joint. Thesystem can determine a second kinematic metric score based on acomparison of the movement signals of the other joint to the baselinemovement profile, where the second kinematic metric score indicates ameasure of a variance from an expected movement. The machine-learnedmodel may be configured to identify the onset of the symptom of thephysical condition further based on at least one of the first kinematicmetric score or the second kinematic metric score.

The system can determine a frequency response of the movement signals.The machine-learned model can be configured to identify the onset of thesymptom of the physical condition further based on this movementfrequency response. The system can measure movement signals at a musclegroup of a foot, a shank, or a thigh of the user, where the movementsignals represent a phase in a gait cycle. The system may create abaseline gait profile using historical movement signals measured at themuscle group. A gait report score can be determined by the system basedon a comparison of the movement signals to the baseline gait profile.The machine-learned model may be configured to identify the onset of thesymptom of the physical condition further based on the gait reportscore.

The modification to the dose or the time associated with the upcomingadministration of the chemical stimulus can be based on a comparison ofmovement signals to a symptom profile, where the movement signalsrepresent a symptom-affected movement of the user. The system maymonitor the movement signals and compare them to the symptom profilecreated using historical movement data representative of movement whilea given user is experiencing the symptom without assistance fromchemical stimulus. In some embodiments, the system may determine achange in user posture depicted in images received from a camera, andthe machine-learned model may be configured to identify the onset of thesymptom of the physical condition further based on the change in userposture.

In some embodiments, motor intent data of the user can be monitored bythe symptom intervention system. The motor intent data can includeelectromyography (EMG) signals. The system can determine a frequencyresponse of the motor intent data, where the frequency response isindicative of an energy of muscle activity of the user, and determine ameasure of fatigue based on a comparison of the frequency response and arested frequency response profile determined using historical EMGsignals. The machine-learned model can be configured to identify theonset of the symptom of the physical condition further based on themeasure of fatigue.

The system may, in response to determining to modify the upcomingadministration of the chemical stimulus, provide biofeedback to theuser. The biofeedback can include one or more of a sensory cue (e.g.,visual, audio, or haptic) to promote a neurotypical movement in theuser. In some embodiments, the system can identify a stimulus metabolismperiod indicating a time period between the intake of the chemicalstimulus and a peak efficacy of the chemical stimulus. The system candetermine to modify the time to administer the chemical stimulus, whichcan be referred to as an administration time, by determining a time atwhich an “off” time duration of the chemical stimulus will begin andupdating the administration time to be earlier, by the stimulusmetabolism period, than the time at which an “off” time duration of thechemical stimulus will begin.

The physical condition can be Parkinson's disease and the symptom iseither a gait freeze, or freeze of gait (FOG), or a tremor. The chemicalstimulus can be one of levodopa, carbidopa, or baclofen. In someembodiments, the physical condition is cerebral palsy and the symptom iscrouch gait.

In another embodiment, a symptom intervention system applies aneuromodulation operation to intervene with a symptom of a physicalcondition. The system monitors movement signals representative ofmovement of a user. For example, the system can monitor kinetic or EMGsignals captured as the user is walking or standing. The system candetermine, using a machine-learned model configured to identify an onsetof a symptom of a physical condition based the monitored movementsignals, that the user is exhibiting a symptom of the symptoms of thephysical condition. The system can, for example, determine whether theuser is experiencing a slowed gait while walking or a tremor whilestanding. Based on a magnitude of the symptom exhibited by the user andcharacteristics of the user, the system can identify a neuromodulationoperation to mitigate the symptom. For example, the neuromodulationoperation can be identified based on a deceleration of a slowed gait orthe acceleration of the user's shaking hands. The neuromodulation isalso identified based on characteristics of the user, which can includehistorical records of applied neuromodulation or feedback related totheir efficacy. The system applies the identified neuromodulationoperation to the user via a wearable neuromodulation system, whichincludes electrodes coupled to the user.

The system can identify a neuromodulation operation depending on thesymptom identified. In response to determining that the symptom is afirst symptom of the physical condition's symptoms, the system candepolarize a first group of neurons of the user. For example, if theuser is experiencing a slowed gait, the system depolarizes neurons tocause muscles to contract. In response to determining that the symptomis a second symptom of the physical condition's symptoms, the system canhyperpolarize a second group of neurons of the user. For example, if theuser is experiencing a tremor, the system hyperpolarizes neurons tocause muscles to relax.

The system may depolarize the first group of neurons by determining atleast one of a set of electrodes, which can be configurable to operateas either a cathode or anode, to operate as a cathode. The system mayhyperpolarize the second group of neurons by determining at leastanother one of the set of configurable electrodes to operate as ananode. In some embodiments, the system compares the movement signals toa symptom profile that is created using historical movement datarepresentative of movement while a given user is experiencing thesymptom without assistance from a chemical stimulus. The system maydepolarize the first group of neurons by determining electricalstimulation parameters based on the comparison of the movement signalsto the symptom profile, the electrical stimulation parameters includinga voltage or current amplitude, a pulse width, a polarity, or afrequency of an electrical stimulation signal. The electricalstimulation signal can be configured by the system to flow between afirst electrode and a second electrode of the wearable neuromodulationsystem's electrodes.

In some embodiments, the system may determine a change in a frequency atwhich the onset of the symptom is identified. The first group of neuronscan be depolarized by determining electrical stimulation parameters ofan electrical stimulation signal based on the change in the frequencyand configuring the electrical stimulation signal to flow between afirst electrode and a second electrode.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a block diagram of a system environment in which a symptomintervention assembly operates, in accordance with at least oneembodiment.

FIG. 2 is a block diagram of the symptom intervention assembly of FIG.1, in accordance with at least one embodiment.

FIG. 3 is a block diagram of a feedback loop for optimizing symptomintervention by a symptom intervention assembly, in accordance with atleast one embodiment.

FIG. 4 shows a configuration of symptom intervention assembly componentson or near a user's body, in accordance with at least one embodiment.

FIG. 5 depicts a GUI for managing chemical stimulus administrationmodifications determined by a symptom intervention assembly, inaccordance with at least one embodiment.

FIG. 6 depicts a GUI for managing neuromodulation applied by a symptomintervention assembly, in accordance with at least one embodiment.

FIG. 7 is a flowchart illustrating a process for determining amodification to an upcoming administration of a chemical stimulus, inaccordance with at least one embodiment.

FIG. 8 is a flowchart illustrating a process for applyingneuromodulation, in accordance with at least one embodiment.

FIG. 9 shows experimental findings of the intervention of drop foot intwo adult users by the symptom intervention assembly described herein.

FIG. 10 shows experimental findings of knee kinematics augmented withFES.

FIG. 11 shows an experimental finding of the movement predictionaccuracy of the symptom intervention assembly.

FIG. 12 shows experimental findings of the impact of fatigue upon muscleelectroactivity.

The figures depict various embodiments for purposes of illustrationonly. One skilled in the art will readily recognize from the followingdiscussion that alternative embodiments of the structures and methodsillustrated herein may be employed without departing from the principlesdescribed herein.

DETAILED DESCRIPTION System Architecture

FIG. 1 is a block diagram of a system environment 100 in which a symptomintervention assembly 110 operates. The system environment 100 includesthe symptom intervention assembly 110, a remote symptom interventionsystem 120, a database 130, a remote therapy system 140, a user device150, and a network 160. The system environment 100 may have alternativeconfigurations than shown in FIG. 1, including for example different,fewer, or additional components. For example, a medical devicedelivering a chemical stimulus may be communicatively coupled with thenetwork 160 to the symptom intervention assembly 110. In anotherexample, the remote therapy system 140 may be omitted from the systemenvironment 100 without compromising the functionality of the symptomintervention assembly 110.

The system environment 100 enables the symptom intervention assembly 110to manage symptoms of its users' physical conditions. The symptomintervention assembly 110 may monitor the user's activity data for anonset of a symptom and apply actuation that intervenes with the symptom.For users of the symptom intervention assembly 110 with Parkinson'sdisease, the symptom intervention assembly 110 can identify an onset ofa symptom of Parkinson's disease such as tremors, FOG, and bradykinesia.

As referred to herein, “activity data” may refer to data representativeof activity of the user's body such as physical movement, electricalmuscle activity, heart rate, respiration, hormone activity,administration of a chemical stimulus, or combination thereof. Activitydata may include movement data such as kinetic, kinematic, pressure, orEMG signals. As referred to herein, the term “movement” may includestillness in addition to motion of a user's body unless context suggestsotherwise. For example, a user's hand may be still and unmoving, asintended by the user, when the onset of a tremor begins and the user'shand begins to move. Here, stillness is an intended movement that can bemonitored by the symptom intervention assembly 110 and the user'smonitored movement is transitioning to movement affected by the tremor.The use of “symptom intervention” and “intervene with a symptom” hereinmay refer to the prevention, reduction in effect, or termination of anoccurrence of a physical condition's symptom. Although the term “users”refer to human users, the systems and methods described herein may besimilarly applied to augmenting movement for animals as well.

In one example, the assembly 110 identifies the onset of bradykinesiathrough monitored IMU signals capturing the user's slowing gait andapplies neuromodulation to treat the slowed movement. The assembly 110can also determine parameters of the neuromodulation to address thepresent characteristics of the user's slowing gait. That is, theassembly 110 can optimize actuation to address not only the symptom butthe symptom as experienced by the user at the current moment, as not allpatients of physical conditions experience their symptoms similarly. Theassembly 110 can achieve this optimization through a feedback process.

In some embodiments, the symptom intervention assembly 110 may receiveor monitor feedback of the applied actuation and modify subsequentlyapplied actuation to optimize its treatment to the user. In the firstexample, the assembly 110 monitors IMU signals capturing the user's gaitas the neuromodulation is applied. Using these monitored signals, theassembly 110 may determine to what extent the user's gait resembles aneurotypical gait or a baseline gait of the user when they are notexperiencing their Parkinson's disease symptoms. This determination mayserve as feedback for the assembly 110 to determine the efficacy of itsapplied neuromodulation and whether the neuromodulation should beadjusted for subsequent IMU signals that show a similar slowing gait.

In a second example, the assembly 110 identifies the onset of tremorsthrough data representative of the efficacy of levodopa. In thisexample, the assembly 110 determines time periods during which levodopa,a chemical stimulus taken for Parkinson's disease, is effective (“on”period) and is diminished in effectiveness (“off” period). These periodscan be determined through monitored data representative of the efficacyof a chemical stimulus such as a user's hormone activity and stimulusdosage (e.g., amount and timing). By determining whether the user iscurrently experiencing an “on” or “off” state of their chemicalstimulus, the assembly 110 can identify a likelihood that an onset of asymptom will occur or when it will occur. Based on this identification,the assembly 110 can determine when to apply a chemical stimulus. In thesecond example, the assembly can cause a levodopa pump to deliverlevodopa to the user so that the user is given enough time to metabolizethe dose and stop the onset of the tremor. Thus, the assembly 110 cantime symptom intervention to optimize the efficacy of a chemicalstimulus with respect to the identified symptom.

Additional details of how the symptom intervention assembly 110identifies onsets of symptoms and determines an actuation to intervenewith the identified onset are described in the description of FIG. 2.Furthermore, Parkinson's disease is a non-limiting example of a physicalcondition that the assembly 110 can help manage. The symptomintervention assembly 110 can intervene in symptoms of various physicalconditions such as cerebral palsy (CP), multiple sclerosis (MS), havingsuffered from a stroke, or any suitable condition affecting the movementof a user.

The symptom intervention assembly 110 enables both personalization andoptimization of symptom intervention for its users. One way in which theassembly 110 personalizes symptom intervention is by using activity datacollected from the user to train a user-specific machine-learned modelthat is used in determining actuation instructions (e.g.,neuromodulation parameters or an amount of a chemical stimulusdelivered) for intervening with the user's subsequent symptoms. Theassembly 110 may optimize symptom intervention by measuring theeffectiveness of the actuation instructions in real time and varyingsubsequently applied actuation instructions based on the measurement.Achieving personalization and optimization using a symptom interventionsystem is described in further detail throughout the description FIGS. 2and 3.

The symptom intervention assembly 110 may have various, wearable formfactors such as exoskeletons, modular electrode straps, leggings, anywearable form factor suitable for targeting a particular muscle group ona user's body, or a combination thereof. The assembly 110 may includevarious components with different form factors that are communicativelycoupled to one another. For example, the assembly 110 may include alegging that is worn underneath regular attire and is equipped withsensors and actuators for performing the symptom intervention describedherein. The legging may be communicatively coupled to a wrist wrap orsleeve of the assembly 110 that is also equipped with sensors oractuators for symptom intervention at the wrist or arms (e.g., reducingtremors at the user's hands). The legging and sleeve may be furthercoupled to a neuromodulation device of the assembly 110 that isimplanted within the user (e.g., a electrical wiring and electrodesembedded within the user to deliver deep brain stimulation (DBS) to theuser's brain). An example configuration of some components of theassembly 110 is depicted in FIG. 4.

The remote symptom intervention system 120 receives and processes datafrom the symptom intervention assembly 110. The data received from thesymptom intervention assembly 110 may include monitored activity data,identified symptoms, applied actuation instructions to intervene withidentified symptoms, and feedback of the symptom intervention (e.g.,user feedback). This data may be used to optimize symptomidentification, generate new actuation instructions, or modify existingactuation instructions. The remote system 120 may use the processed datato provide actuation instructions for the assembly 110 to execute. Theremote symptom intervention system 120 may have functionality similar tothat of the symptom intervention system 220 described in FIG. 2. Theremote system 120 may be hosted on a server or computing device (e.g., asmartphone) that communicates with the symptom intervention assembly 110via the network 160.

In some embodiments, the remote symptom intervention system 120 trainsand applies one or more machine-learned models configured to identify anonset of a physical condition's symptom based on monitored activitydata. In one embodiment, the remote symptom intervention system 120trains the models based on activity data collected by sensors onboardthe symptom intervention assembly 110. The assembly 110 sends, via thenetwork 160, activity data to the remote symptom intervention system 120and leverages the trained machine learning models to receive, from theremote symptom intervention system 120, an identification of an onset ofa symptom as output by the one or more models. The remote symptomintervention system 120 may maintain models that are generalized tomovement across a population or customized to a particular user,activity type, any suitable phenotypic trait, or a combination thereof.The training and application of machine learning models used for symptomintervention is further described in the description of FIG. 2.

The database 130 stores various data for maintaining models of thesymptom intervention assembly 110. The data may be used to create astatistical model or train a machine-learned model. The data stored inthe training database 130 may include labeled or unlabeled activity dataand associated onset of a symptom, labels associated with symptoms orphysical conditions, or templates associated with sequences of musclefirings for given movements. The symptom intervention assembly 110 mayaccess the stored data to maintain models of the symptom interventionsystem 220. The symptom intervention assembly 110 may provide itsmeasured data or feedback to the database 130. The provided data may beorganized in a data structure including the provided data, biographicalinformation identifying the user or the user's phenotypic traits, and alabel identifying the symptom associated with the provided data.

The remote therapy system 140 enables a third party to monitor theuser's activity and symptom experiences (e.g., as identified by thesymptom intervention assembly 110) and analyze the information tofurther assist the user with their symptom management. A third party canbe a medical professional. For example, a doctor uses the remote therapysystem 140 to monitor a user's movement and adjust an actuationinstruction upon identifying that the patient's symptoms are not managedproperly under the current actuation instruction being applied. Theremote therapy system 140 may be a software module that the third partymay execute on a computing device (e.g., a smartphone). In someembodiments, the remote therapy system 140 is a standalone device thatmay be communicatively coupled to the symptom intervention assembly 110to manually adjust or generate actuation signals used to augment theuser's motion (e.g., overriding the symptom intervention assembly 110).The remote therapy system 140 may include an input interface for thethird party to specify parameters of an actuation instruction (e.g., theamplitude and frequency of FES signals) and when to apply them. In someembodiments, a third party is not in the medical community but canmonitor the user's activity and symptoms to observe a progress of theirphysical condition, which may be relayed by that third party to amedical professional. For example, family member of the user or athleticcoach can help the user track their symptoms remotely through the remotetherapy system 140.

The remote therapy system 140 may provide actuation instructions to beapplied by the mobility augmentation system 130. In some embodiments, auser of the remote therapy system 140 (e.g., a doctor) may specify whento apply neuromodulation and the electrode configuration of the symptomintervention assembly 110 through which the neuromodulation should beapplied. For example, the doctor may specify how and when to stimulate auser's gait based on a video camera, which may be a sensor of theassembly 110 that is communicatively coupled to the remote therapysystem 140, that captures the patient's gait. The doctor-specifiedactuation instruction may be communicated from the remote therapy system140 to the symptom intervention system 110 over the network 160.

The user device 150 may be a personal computer (PC), a tablet PC, asmartphone, or any suitable device capable of executing instructionsthat specify actions to be taken by that device. The user device 150 mayinclude a processor (e.g., a central processing unit (CPU), a graphicsprocessing unit (GPU), a digital signal processor (DSP), one or moreapplication specific integrated circuits (ASICs), one or moreradio-frequency integrated circuits (RFICs), or any combination ofthese), a memory, a user interface to receive user inputs or provideoutputs to the user (e.g., a visual display interface including a touchenabled screen, a keyboard, microphone, speakers, etc.). The visualinterface may include a software driver that enables displaying userinterfaces on a screen (or display). The user device 150 may enable auser to manage the symptom intervention assembly 110. For example, thesymptom intervention assembly 110 may cause a GUI to be generated at ascreen of the user device 150, where the GUI includes input fields toapprove, deny, or modify an actuation instruction to be applied tointervene with a symptom. The assembly 110 may also cause a GUI to begenerated at the user device 150 that allows the user to providefeedback indicating a measure of approval with the actuation instructionapplied. The assembly 110 may cause the GUI to be generated by hostingdocuments (e.g., HyperText Markup Language (HTML) documents) andtransmitting them to a web browser or application of the user device 150that generates GUI elements at the device 150. Examples of GUIs areshown in FIGS. 5 and 6.

The network 160 may serve to communicatively couple the symptomintervention assembly 110, the remote symptom intervention system 120,the database 130, the remote therapy system 140, and the user device150. For example, the symptom intervention assembly 110 and the remotetherapy system 140 are configured to communicate via the network 160. Insome embodiments, the network 160 includes any combination of local areaand/or wide area networks, using wired and/or wireless communicationsystems. The network 160 may use standard communications technologiesand/or protocols. For example, the network 160 includes communicationlinks using technologies such as Ethernet, 802.11, worldwideinteroperability for microwave access (WiMAX), 3G, 4G, 5G, code divisionmultiple access (CDMA), digital subscriber line (DSL), etc. Examples ofnetworking protocols used for communicating via the network 160 includemultiprotocol label switching (MPLS), transmission controlprotocol/Internet protocol (TCP/IP), hypertext transport protocol(HTTP), simple mail transfer protocol (SMTP), and file transfer protocol(FTP). Data exchanged over the network may be represented using anysuitable format, such as hypertext markup language (HTML) or extensiblemarkup language (XML). In some embodiments, all or some of thecommunication links of the network 160 may be encrypted using anysuitable technique or techniques.

Although the components of the system environment 100 are shown asconnected over the network 160, one or more components may functionwithout being connected to the network 160. For example, the symptomintervention assembly 110 may function offline when it is not able toconnect to the network 160. When the assembly 110 is able to reconnectto the network 160, the assembly 110 may upload monitored activity data,symptom identification results, or determined symptom intervention tothe database 130 or the remote therapy system 140 via the network 160.

Symptom Intervention Assembly

FIG. 2 is a block diagram of the symptom intervention assembly 110 ofFIG. 1, in accordance with at least one embodiment. The symptomintervention assembly 110 monitors activity data of a user to identifyan onset of a symptom and an intervention for the symptom. Components ofthe symptom intervention assembly 110 include sensors 201, dosing 202, apower source 203, communications circuitry 204, and a microcontroller(MCU) 205. The sensors 201 of the symptom intervention assembly 110monitor a user's activity data. The symptom intervention assembly 110includes the MCU 205, which can store and execute a symptom interventionsystem 220 to identify the onset of a symptom and determine anintervention for the symptom. The symptom intervention assembly 110 canapply the determined intervention through dosing 202.

The sensors 201 measure the user's activity. A user's activity mayinclude movement or body measurements related to movement such as heartrate or respiration rate affected by movement. A user's movement mayinclude movements affected by chemical stimulus, the efficacy of whichcan be measured through hormone level or biomolecule levels affected bythe chemically stimulated hormones. The user's activity can be measuredbefore, during, or after application of an actuation to intervene withthe symptom. User activity measured before actuation may be used todetermine which actuation instruction to enable. User activity measuredduring or after the application of the actuation may be used to scorethe applied actuation. The sensors 201 may be one or more of an IMU, EMGsensor, camera, heart rate sensor, pressure sensor bed or foot pressuresensor, force sensor, glucose monitor, or any suitable sensor formeasuring movement or body measurements related to movement. The sensors201 may include an EMG sensor, which may include electrodes forcollecting EMG data, or the symptom intervention assembly 110 may obtainEMG data from electrodes of the dosing 202. The sensors 201 may includea galvanic skin sensor, which may include dedicated electrodes formeasuring changes in sweat gland activity on the skin or may use theelectrodes of the dosing 202 to collect the galvanic skin response data.

The sensors 201 may be located at various locations on the user's body.For example, a pressure sensor bed may be placed in the user's rightshoe to measure the user's right foot pressure as the user completes agait. A set of sensing electrodes may be placed at the shank of theuser's right leg to measure the intended movement data before and duringthe gait. The sensors 201 may be communicatively coupled to the MCU 205to provide the measured data for determining or optimizing actuationinstructions applied by the symptom intervention assembly 110. In someembodiments, the locations of the sensors 201 includes the joints of thebody (e.g., ellipsoid joint and saddle joint). For example, the sensors201 may measure movement at the ellipsoid and saddle joints using IMU'sto determine the quality of a user's grip (e.g., how far the user isable to close their hand into a fist).

The sensors 201 may include a sensor that is not co-located with othersensors of the sensors 201 (e.g., the sensor does not rely upon thepower source 203 for power). For example, the sensors 201 may include acamera directed at the user and configured to capture image data of theuser's movements. The camera may be communicatively coupled to thesymptom intervention system 220 to provide captured image data. Thesymptom intervention system 220 may then determine an actuationinstruction to assist in the user's movement depicted in the image dataor user's movement expected to follow the movement depicted in the imagedata.

The dosing 202 perform actuation instructions determined by the symptomintervention system 220 for intervening with a symptom of a physicalcondition. The dosing 202 may perform actuation instructions for varioustypes of actuation such as titration (e.g., of a chemical stimulus),neuromodulation, biofeedback, and FES. The dosing 202 may be located atvarious locations on the user's body. For example, electrodes forneuromodulation may be located at the user's brain and electrodes forFES are located at the user's limbs. The dosing 202 may becommunicatively coupled (e.g., wireless or wired) to the symptomintervention system 220 to receive actuation instructions. For example,neuromodulation electrodes may be wired to a controller implanted withinthe user, which is wirelessly coupled to an MCU of a wearablestimulation array wrapped around one of the user's leg to assist withtheir walking. In this example, the MCU of the array may include thesymptom intervention system 220 and coordinate actuation instructionsfor both the FES electrodes and the neuromodulation electrodes toimprove the user's gait.

The dosing 202 may be actuators that include hardware to perform thevarious types of actuation. To perform titration, the dosing 202 caninclude a pump coupled to a tube to deliver doses of a chemical stimulusautomatically to the user. To apply neuromodulation, the dosing 202 mayinclude electrodes connected to the user's brain to deliver low voltageelectrical stimulation. To apply biofeedback, the dosing 202 may includea speaker, vibrating mechanism, display, LEDs, or a combination thereof.To perform FES, the dosing 202 include an array of electrodes, which maybe configurable by the symptom intervention system 220, to apply anelectrical signal to stimulate a muscle group and assist with aparticular movement (e.g., a gait). In some embodiments, the symptomintervention assembly 110 may leverage actuators from another device(e.g., vibrating mechanisms of the user device 150) by transmittinginstructions to the other device to apply an actuation instruction(e.g., biofeedback vibrations).

The power source 203 may be a mobile power source such as a battery or afixed power source such as an outlet connection to power. The powersource 203 may provide power for actuation by the dosing 202. Forexample, the dosing control module 225 may activate or deactivate anelectrical connection between the power source 203 and FES electrodes ofthe dosing 202 to control electrical stimulation. The power source 203may provide power for biofeedback actuation that includes mechanicalstimulation via a vibrating motor or audio signals output via a speakerto provide cues for the user to walk. In some embodiments, the powersource 203 provides power for chemical stimulus administrationmodification. For example, the power source 203 may support a titrationsystem that involves an external, portable pump that delivers levodopafor Parkinson's disease through a tube (e.g., percutaneous endoscopicgastrostomy with jejunal tube) to the intestine.

The communications circuitry 204 enables the symptom interventionassembly 110 to communicate over a network (e.g., the network 160). Thecommunications circuitry 204 may be configured to establish a connectionbetween the symptom intervention assembly 110 and the Internet using oneor more of a Wi-Fi, cellular, local area network (LAN) interface, or anysuitable interface for wireless communication. The communicationscircuitry 204 may be configured to transmit and receive data fromcommunications circuitry of other devices (e.g., other wearablestimulation arrays or a user device). In some embodiments, thecommunications circuitry 204 may also enable wired communication throughvarious mediums such as fiber-optic, USB, serial, coaxial, or anysuitable cable for wired networking.

The MCU 205 represents one or more processors such as a microprocessor,a central processing unit, or the like. More particularly, theprocessing device may be complex instruction set computing (CISC)microprocessor, reduced instruction set computing (RISC) microprocessor,very long instruction word (VLIW) microprocessor, or a processorimplementing other instruction sets, or processors implementing acombination of instruction sets. The MCU 205 may also be one or morespecial-purpose processing devices such as an application specificintegrated circuit (ASIC), a field programmable gate array (FPGA), adigital signal processor (DSP), network processor, or the like. The MCU205 may be configured to execute instructions for performing theoperations and steps described herein.

The MCU 205 hosts and executes a symptom intervention system 220, whichincludes software modules such as a symptom identifier module 224, adosing control module 225, a graphical user interface (GUI) module 226,and a model training engine 227. The symptom intervention system 220includes models, such as a general symptom identification model 228 anda user-specific symptom identification model 229, for identifying theonset of a symptom of a physical condition. The system 220 may alsoinclude dosing model 230 for determining an actuation instruction toapply based on the identified symptom. The symptom intervention system220 includes databases such as an actuation instruction database 221, auser profile database 222, and a physical condition profile database223. The symptom intervention system 220 may have alternativeconfigurations than shown in FIG. 2, including different, fewer, oradditional components. For example, one or more of the databases 221,222, or 223 may be stored remotely rather than on a memory of the MCU205 (e.g., contents stored in the database 130) and may be accessiblethrough the network 160. In another example, an additional reportgeneration module may generate a report of the applied actuation and themonitored activity data associated with the actuation and provide thereport to the remote therapy system 140.

The software modules of the symptom intervention system 220 may bemodified using a scripting engine that enables real-time programmabilityof the systems. The scripting engine enables new or personalizedalgorithms to be deployed without a need to update the systems' firmwareor reflash the hardware with new code.

The actuation instruction database 221 stores actuation instructions forenabling the dosing 202 to intervene in the occurrence of a symptom of aphysical condition of the user. An actuation instruction may specify anactuation type, duration of actuation, location of actuation, anysuitable parameter of the actuation, or combination thereof. Forexample, an actuation instruction for an electrical stimulation signalmay include parameters specifying an amplitude (e.g., volts), frequency,and pulse width of the signal, a duration to apply the stimulation tothe user, and a location at the user's shank of their left leg to applythe stimulation. An actuation types classifies the actuation into amanner of actuation such as electric, mechanic, haptic, audio, visual,pneumatic, hydraulic, or a combination thereof. Additional examples ofactuation types include chemical stimulus administration (e.g.,titration), neuromodulation, biofeedback, and FES electrodes. Eachactuation type is described in more detail with respect to thedescription of the dosing 202. The duration of the actuation may varybased on the actuation type. For example, neuromodulation may lastshorter (e.g., ten seconds) than biofeedback (e.g., as long as the useris walking). The location of actuation may indicate which hardwarecomponents of the symptom intervention assembly 110 apply the actuation.For example, the location of actuation may be a subset of the FESelectrodes or a subset of the neuromodulation electrodes of the dosing202. In another example, the location of actuation may be a particularwearable stimulation array of multiple stimulation arrays worn by theuser. Examples of wearable stimulation arrays may be found in U.S.patent application Ser. No. 17/397,669 and 17/397,674, filed Aug. 9,2021, which are incorporated herein by reference.

The user profile database 222 stores information regarding one or moreusers. The users may be users of the symptom intervention assembly 110,which includes memory to store the user profile database 222. In someembodiments, information of users of the wearable stimulation arraystransmitted to the user profile database 222, which is located at aremote server such as the remote symptom intervention system 120. Theuser profile database 222 may include user information such as bodymeasurements, movement measurements, and chemical stimulusadministration information. Examples of body measurements includeheight, weight, body mass index, body temperature, heart rate, galvanicskin response, hormone activity, or any suitable measurement of anatural activity the user's body undergoes. Examples of movementmeasures may include a walking pace, a number of steps taken, anelevation gain, exercises performed, or any suitable measurement ofphysical movement that the user takes. In some embodiments, chemicalstimulus administration is a medical prescription, and theadministration information includes when the user takes a medicine, howmuch medicine the user takes per dose, the type of medicine, or anysuitable characteristic of the prescription.

User information stored in the user profile database 222 may be providedby the user manually (e.g., the user entering their height), tracked bya wearable device such as the stimulation array described herein or awearable fitness tracker (e.g., a smartwatch), or provided by a thirdparty (e.g., a doctor at the remote therapy system 140). The informationstored within the database 222 may be edited. For example, a medicaldoctor at the remote therapy system 140 may update the chemical stimulusadministration of the user, and the updates may be transmitted from theremote therapy system 140 to the symptom intervention assembly 110through the network 160. In another example, the symptom interventionsystem 220 can store and edit information at the user profile database222. For example, modifications to the chemical stimulus administrationdetermined by the dosing control module 225 may be stored within theuser profile database 222.

The user information stored in the user profile database 222 may alsoinclude information tracked by sensors (e.g., the sensors 201 of thesymptom intervention assembly 110). For example, the user profiledatabase 222 may store a record of the movement data representingstimulated movement of the user by the dosing 202 of the symptomintervention assembly 110. In some embodiments, the user profiledatabase 222 stores feedback from the user indicating a measure ofapproval of the symptom intervention. The feedback may be inferredthrough measurements taken by the symptom intervention assembly 110 ormanually provided by the user. For example, the symptom interventionassembly 110 measures and compares user movement assisted by FES withmovement assisted by biofeedback, where the FES and biofeedback areintended to help the user with their gait. The symptom interventionassembly 110, which may include a sensor located at the user's shoe,measures kinetic movement data representing movement in a gait (e.g.,dorsiflexions) of differing qualities assisted by the two actuationinstructions. The symptom intervention assembly 110 compares the kineticmovement data of the movements to kinetic movement data of aneurotypical dorsiflexion and determines that the FES actuationinstruction stimulated movement that is more similar to neurotypicalmovement than the biofeedback instruction stimulated. The result of thiscomparison may be stored in the user profile database 222 as feedbackindicating that FES stimulation works better for the user thanbiofeedback for improving dorsiflexion.

In another example, a user manually provides feedback that is stored inthe user profile database 222. The symptom intervention assembly 110 maybe communicatively coupled to a user device (e.g., the user device 150)through which the user can provide feedback of the intervention applied,or proposed to be applied, by the symptom intervention assembly 110. Thefeedback may indicate a measure of comfort, effectiveness, or approvalof the intervention. Example GUIs through which a user can providefeedback are shown in FIGS. 5-6.

The physical condition profile database 223 stores information regardingone or more physical conditions and corresponding symptoms. Examplephysical conditions include Parkinson's disease, multiple sclerosis,cerebral palsy, having suffered from a stroke, or any other conditionthat affects a user's ability to move as desired. Each physicalcondition may be associated with respective symptoms that indicate thatthe user is affected by the physical condition. Parkinson's disease maybe associated with impairments to movement such as tremors, rigidity(e.g., gait freeze or freeze of gait (FOG)), bradykinesia, andimbalance. Multiple sclerosis may be associated with similar impairmentsto movement such as tremors and imbalance and additional impairmentssuch as ataxia (i.e., unstable walking) and clumsiness of a limb.Cerebral palsy may be associated with similar impairments to movementsuch as tremors, rigidity, and difficulty walking (e.g., crouch gait).

The physical condition profile database 223 may store symptom signalprofiles for symptoms of a physical condition. Symptom signal profilesmay be a quantitative representation of the symptom as it is experiencedby a given user. For example, a symptom signal profile of a tremor mayinclude kinematic signals measured by IMU sensors located near themuscle group experiencing the tremor (e.g., at the user's hand orforearm). In another example, a symptom signal profile of imbalance mayinclude kinematic signals measured by IMU sensors at a left leg and aright leg, the signals demonstrating muscles at one leg being weakerthan muscles at the other. Symptom signal profiles may be collectedacross a population of users having a physical condition, and signals ofthe profiles may be averaged to obtain a general symptom signal profile.The symptom signal profiles may characterize respective symptomsthroughout their duration (e.g., from an onset of a tremor to when thetremor stops). The onset of a symptom may be characterized by an initialportion of a symptom signal profile. For example, for a symptom signalprofile including kinematic signals of a FOG over time, the onset of theFOG may be characterized by the first second of the symptom signalprofile.

The physical condition profile database 223 may store informationrelated to the onset of a symptom in addition or alternative to thesymptom signal profile. An onset of a symptom may be characterized bycontextual information such as a schedule or a location of the user. Forexample, a FOG may occur when the user is walking in a large crowd orentering an elevator, activities which can be deduced by a location or aschedule of the user. The onset of a symptom may be characterized byactivity information such as a heart rate, respiration rate, hormoneactivity, or information about an administration of a chemical stimulus.For example, FOG may occur when a user is distressed, anxious, orfrightened, which may coincide with an increased heart rate orrespiration rate. In another example, FOG may occur when a chemicalstimulus's efficacy has diminished since the time of its dose. A levelof insulin of a user, an example of hormone activity, when experiencingFOG and information about when a chemical stimulus for reducing FOGoccurrences was administered may be used to characterize the onset ofthe symptom. The database 223 may store contextual information andactivity information associated with the onset or full duration of thesymptom.

The symptom identifier module 224 identifies an onset of a symptom of auser's physical condition. The onset of a given symptom may be one ormore measurable signals or information indicating that the user'smonitored movement is transitioning to movement affected by the givensymptom. The measurable signals (e.g., movement signals) and information(e.g., contextual information) may be measured at a time period betweenthe end of neurotypical movement, or movement unaffected by the physicalcondition, and the start of movement impacted by the symptom. Thesymptom identifier module 224 may monitor a user's activity data, anduse the monitored activity data to identify the onset of a symptom.Activity data may be monitored using the sensors 201 or providedmanually (e.g., a user or doctor provides the symptom interventionsystem 220 with the user's medical prescription).

The symptom identifier module 224 determines whether to intervene withan actuation. In some embodiments, the symptom identifier module 224determines to intervene when the onset of a symptom is identified with aconfidence score meeting or exceeding a threshold confidence score. Thesymptom identifier module 224 determines not to intervene when the onsetof a symptom is identified with a confidence score below a thresholdconfidence score. The symptom identifier module 224 may use one or morethreshold confidence scores for respective symptoms. For example, athreshold confidence score of 80% confidence may be used for identifyinga tremor for Parkinson's disease while a threshold confidence score of60% may be used for crouch gait for CP. The symptom identifier module224 may adjust the threshold confidence score. For example, as thesymptom intervention system 220 receives user feedback of the appliedactuation indicating that the applied actuation is approved, the symptomidentifier module 224 may lower the threshold confidence score.

The symptom identifier module 224 may identify both the onset of asymptom and which symptom of various symptoms whose onset is beingidentified. The symptom identifier module 224 may apply a model tomonitored activity data, where the model outputs a symptom and anassociated confidence score that the identification is accurate. Byapplying the model to activity data monitored at a time period betweenthe end of neurotypical movement and the initial impact of the symptomon the user, the symptom identifier module 224 can identify the onset ofthe symptom of a physical condition. The model may be a machine learnedmodel trained on data monitored at the onset of a symptom, and thus ableto identify subsequent onsets. Training of the models is describedfurther in the description of the model training engine 227.

The symptom intervention system 220 may manage a model for each symptomit identifies, where the respective models are trained on data for therespective symptom. For example, a first machine-learned model istrained with data representing the onset of a tremor for Parkinson'sdisease and a second machine-learned model is trained with datarepresenting FOG for Parkinson's disease. The symptom identifier module224 may apply both models to monitored activity data and determine thatthe user is experiencing FOG with a confidence score of 85%, asdetermined by the second machine-learned model, and the user isexperiencing a tremor with a confidence score of 5%, as determined bythe first machine-learned model. Because the confidence score is greaterfor one symptom than another, the symptom identifier module 224 mayidentify that the user is experiencing the onset of the symptom withgreater confidence score (e.g., identifies FOG and not tremors).

Various types of activity data may be used to identify an onset of asymptom. Examples of which include movement signals, hormone activity,kinematic scores, movement cadence, gait report, posture changes, andfatigue. The symptom identifier module 224 may apply movement signalsmeasured by the sensors 201 to a machine-learned model trained onmovement signals to identify an onset of a symptom of a physicalcondition. In one example, the symptom identifier module 224 receivesmovement signals measured at an IMU sensor and foot pressure sensor ofthe sensors 201. These monitored movement signals may represent thekinematics of a toe-off in a gait cycle as captured at a leg and foot atone side of the user's body. The symptom identifier module 224 thenapplies the received movement signals to a machine-learned model trainedon movement signals representative of shuffling gait, a symptom ofphysical conditions such as Parkinson's disease and having suffered froma stroke. Using the machine-learned model, the symptom identifier module224 may determine that an actuation instruction should be applied tointervene with the shuffling gait. For example, the module 224 maynotify the dosing control module 225 of the onset of the shuffling gaitafter the machine-learned model identifies its onset in the monitoredmovement signals with a confidence score above a threshold confidencescore.

The symptom identifier module 224 may apply hormone activity measured bythe sensors 201 to a machine-learned model trained on hormone activityto identify an onset of a symptom of a physical condition. Hormoneactivity may include measurements for a level of a hormone or abiomolecule affected by the hormone. In one example, the symptomidentifier module 224 receives glucose levels measured at a glucosemonitor. These monitored glucose levels may be commensurate with theuser's insulin levels and may represent the current efficacy of achemical stimulus taken to treat physical condition symptoms. Forexample, levodopa-carbidopa is a chemical stimulus taken to treatsymptoms of Parkinson's disease. However, the intake oflevodopa-carbidopa may affect insulin-stimulated glucose transport.Therefore, a glucose monitor may show that a user has a certain glucoselevel when effects of levodopa-carbidopa (e.g., promoting dopamine) areactive (e.g., an “on” period) and a different glucose level when theeffects of levodopa-carbidopa are diminished (e.g., an “off” period).The symptom identifier module 224 then applies the received glucoselevels to a machine-learned model trained on glucose levelsrepresentative of users experiencing an “off” period oflevodopa-carbidopa.

When levodopa-carbidopa users experience “off” periods, they are morelikely to experience symptoms of Parkinson's disease. Accordingly, usingthe machine-learned model, the symptom identifier module 224 maydetermine that an “off” period is occurring and that an actuationinstruction should be applied to intervene with a symptom ofParkinson's. For example, the module 224 may determine that an onset ofa Parkinson's disease symptom is likely occurring or will occur due tothe detected “off” period of the chemical stimulus. The module 224 maythen trigger the dosing control module 225 to determine a modificationto the titration of levodopa-carbidopa (e.g., time between doses oramount administered at a particular dose). In some embodiments, themodule 225 may also determine an actuation instruction that includesgenerating a notification for the user (e.g., at the user device 150) totake their dose of the chemical stimulus (e.g., a pill) so that dose canmetabolize and intervene with the symptom in a timely manner. An exampleof this determination is further described in the description of FIG. 7.

The symptom identifier module 224 may determine kinematic scores frommovement signals measured by the sensors 201, and apply the determinedkinematic scores to a machine-learned model trained on kinematic scoresto identify an onset of a symptom of a physical condition. In oneexample, the symptom identifier module 224 receives movement signalsmeasured at IMU sensors at the knee joints of the user's left and rightlegs. Comparison of these monitored movement signals may represent thesymmetry of a user's gait. For example, the symptom identifier module224 may compare kinematic signals representing the swing phase of auser's gait at their left knee joint to the corresponding kinematicsignals at the user's right knee joint. In response to determining ahigh level of symmetry between the two sets of right and left knee jointkinematic signals, the symptom identifier module 224 may determine notto modify the administration of a chemical stimulus taken by the user totreat their physical condition. In response to determining a low levelof symmetry between the two sets of kinematic signals, the symptomidentifier module 224 may determine to modify the administration of thechemical stimulus. The module 224 may determine whether a symmetry levelis high or low using various signal processing techniques such asdetermining a cross-correlation, time-shifting, and determining adifference between the two signals. The module 224 may apply thedetermined level of symmetry to a machine-learned model trained onsymmetry levels representative of an imbalanced gait, which is a symptomof physical conditions such as Parkinson's disease and MS. Using themachine-learned model, the symptom identifier module 224 may determinethat an actuation instruction should be applied to intervene with theimbalanced gait. For example, the module 224 may notify the dosingcontrol module 225 of the onset of the imbalanced gait after themachine-learned model identifies its onset in the low level of symmetrybetween kinematic signals at the user's two knee joints.

The symptom identifier module 224 may apply a cadence of movementsignals measured by the sensors 201 to a machine-learned model trainedon movement cadence to identify an onset of a symptom of a physicalcondition. In one example, the symptom identifier module 224 receivesmovement signals measured at an IMU sensor located at a user's leg tomeasure kinematic signals representative of the user's gait. The symptomidentifier module 224 determines a frequency response of the user'sgait, or the user's gait cadence. As gait movements are typically cyclicin nature, a neurotypical gait does not deviate substantially from anaverage frequency. However, a user with a physical condition such asParkinson's disease may experience symptoms such as bradykinesia, whichcan suddenly slow or freeze the user's gait. The symptom identifiermodule 224 may determine a change in gait cadence, and determine whetherthe change warrants triggering the dosing control module 225 to modifyan administration of a chemical stimulus. In one example, the module 224determines that the cadence has decreased greater than a thresholdamount and triggers the module 225 to modify a titration of levodopataken by the user to treat their Parkinson's disease. In anotherexample, the module 224 determines that the cadence has reached zero,indicating that the user may be experiencing FOG, and trigger the module225 to modify the titration of levodopa. In yet another example, themodule 224 applies the change in gait cadence to a machine-learned modeltrained on gait cadence changes representative of bradykinesia. Usingthe machine-learned model, the symptom identifier module 224 maydetermine that an actuation instruction should be applied to intervenewith the bradykinesia.

The symptom identifier module 224 may determine gait report usingmovement signals measured by the sensors 201 and apply the gait reportto a machine-learned model trained on gait reports to identify an onsetof a symptom of a physical condition. The symptom identifier module 224uses historical movement signals measured at a muscle group used in agait cycle (e.g., a foot, shank, a thigh, or combination thereof) tocreate a baseline gait profile. A single gait cycle may be composed of astance phase and a swing phase. A stance phase may include, in sequenceof the gait cycle, a heel strike, a loading response, mid-stance,terminal stance, and pre-swing. A swing phase may include, in sequenceof the gait cycle, a toe-off, mid-swing, and terminal swing. Thebaseline gait profile may include movement signals representative of oneor more of the phases or the movements within the respective phases. Forexample, a baseline gait profile may include kinematic signals measuredthrough a foot pressure sensor as a user is moving through the stancephase and rested such that the baseline gait profile represents arelatively optimal stance phase performance for the user. The baselinegait profile can be used by the symptom identifier module 224 to compareto subsequently monitored movement signals by the foot pressure sensorto determine how the user is performing their stance phase relative totheir baseline performance. This comparison may be referred to herein asa “gait report.”

In one example of using a gait report to identify an onset of a symptomof a physical condition, the symptom identifier module 224 receivesmovement signals measured at an IMU sensor and foot pressure sensor ofthe sensors 201. These monitored movement signals may represent thekinematics of a swing phase in a gait cycle as captured at a leg andfoot at one side of the user's body. The symptom identifier module 224creates a baseline gait profile of the user's swing phase usinghistorical movement signals measured at the user's leg (e.g., shankmuscle) and foot. The symptom identifier module 224 determines a scorefor a gait report based on a comparison of the monitored movementsignals to the baseline gait profile. For example, the symptomidentifier module 224 may determine the similarity of the monitoredkinematic signals to the historical kinematic signals in the baselinegait profile. The determined level of similarity may be a gait reportscore within the gait report. The symptom identifier module 224 mayapply scores within the gait report to a machine-learned model trainedon gait reports representative of shuffling gait, a symptom of physicalconditions such as Parkinson's disease and having suffered from astroke. Using the machine-learned model, the symptom identifier module224 may determine that an actuation instruction should be applied tointervene with the shuffling gait.

In some embodiments, the symptom identifier module 224 may identify anonset of a symptom of a physical condition using a comparison tomovement signals taken when the user is moving without assistance from achemical stimulus. Similar to the baseline gait report, a baselinesymptom profile may be created by the module 224, where the baselinesymptom profile is created using historical movement data representativeof movement while a user is experiencing the symptom without assistancefrom a chemical stimulus. The baseline symptom profile can be similar tothe baseline gait report in that they both represent the historicalmovement of a user, but the symptom profile may be generally applicableto movements in addition to a gait. The symptom identifier module 224may compare monitored movement signals to the baseline symptom profileto determine a movement score representative of a level of similaritythe user's current movement is to movement when the user is experiencingthe symptom without chemical stimulus assistance. The module 224 may usea threshold score to identify that the user is experiencing an onset ofa symptom. For example, the movement score indicates a level ofsimilarity that meets a threshold score indicating that the user isexperiencing a tremor. In response, the module 224 may trigger thedosing control module 225 to determine a modification to the chemicalstimulus administration. In some embodiments, the symptom identifiermodule 224 may apply the determined movement score to a machine-learnedmodel trained on movement scores to identify an onset of a symptom of aphysical condition. If the machine-learned model outputs a confidencescore above a threshold confidence score that a user is experiencing,for example, tremors of their Parkinson's disease, the module 224 maynotify the dosing control module 225 of the onset of the tremors.

The symptom identifier module 224 may apply image data captured by thesensors 201 to a machine-learned model trained on image data to identifyan onset of a symptom of a physical condition. Cameras may capture auser's posture or change therein, which may indicate the onset of asymptom of a physical condition. In one example, the symptom identifiermodule 224 receives image data captured at a camera of the sensors 201.The captured image data depicts a user's change in upright posture to animbalanced posture (e.g., the leg muscles of one leg experiencespasticity and causes the imbalance). The symptom identifier module 224then applies the image data to a machine-learned model trained on imagedata representative of spasticity, a symptom of Parkinson's disease, CP,and MS. The machine-learned model may identify the onset of spasticityabove a threshold confidence score, and the symptom identifier module224 may trigger the dosing control module 225 to apply an actuationinstruction to intervene with the spasticity.

The symptom identifier module 224 may apply data representative of alevel of fatigue to a machine-learned model trained on datarepresentative of fatigue to identify an onset of a symptom of aphysical condition. Fatigue may be associated with diminishing effectsof a chemical stimulus (e.g., an “off” period of levodopa) andcorrelated with an increased in likelihood that an onset of a physicalcondition's symptom will occur. The symptom identifier module 224 mayapply EMG signals, which can represent a user's level of fatigue, to amachine-learned model to identify an onset of a symptom. EMG signalsreflect muscle electroactivity, and their frequency may reflect thelevel of fatigue. As a user grows fatigued, the frequency of EMG signalsmay decrease. In one example, the symptom identifier module 224 receivesEMG signals measured at an EMG sensor of the sensors 201. The module 224may apply the received EMG signals to a machine-learned model trained onhistorical EMG signals measured when the user is rested such that themachine-learned model identifies whether the received EMG signalsindicate the user is rested or fatigued. Additionally or alternatively,the symptom identifier module 224 may create a rested frequency responseprofile of the user using historical EMG signals, where the restedfrequency response profile indicates the average frequency response of auser when they are rested (e.g., performing a gait cycle without feelingfatigued). Based on a comparison of the received EMG signals to therested frequency response profile, the symptom identifier module 224 mayidentify that an onset of a symptom is likely to occur or is occurring.This comparison or the received EMG signals themselves may be measuresof the user's fatigue. The module 224 may also apply a machine-learnedmodel to the results of the comparison to identify the onset of thesymptom. In response to determining that the measure of fatigue isindicative of a likely onset of the user's physical condition symptom,the module 224 may notify the dosing control module 225 of the onset ofthe symptom to determine an appropriate actuation instruction.

The symptom identifier module 224 may determine context information toidentify whether an onset of a symptom is occurring. Symptoms ofphysical conditions may be more likely to occur under certainenvironmental conditions. For example, those with Parkinson's diseaseare more likely to experience FOG when they are walking through narrowpassages or doorways, entering or exiting elevators, in a busy crowd, orwhen they are anxious or frightened. The sensors 201 may provideinformation insightful to the user's environment. For example, a heartrate sensor of the sensors 201 may indicate that the user's heart rateis becoming elevated and is experiencing anxiety. Although not depicted,the symptom intervention assembly 110 may be GPS enabled such that theassembly 110 can determine a location of the user. Alternatively, theassembly 110 can periodically request the user's location from aGPS-enabled device that it is communicatively coupled with through thecommunications circuitry 204. In one example, a GPS location of the usermay indicate that the user is at a sports venue and is more likely to bewithin a busy crowd or walk through narrow passageways (e.g.,bleachers). IN some embodiments, context information is provided by theuser and accessed by the symptom identifier module 224. For example, theuser provides their schedule of events to a calendar application ontheir device (e.g., the user device 150) and the symptom identifier 224queries the calendar application to determine the event that the user islikely to be doing at the current time. The symptom identifier module224 may quantify this context information and apply a machine-learnedmodel trained on context information to identify that the user isexperiencing a symptom (e.g., FOG).

The various types of activity data for identifying an onset of a symptomby the symptom identifier module 224 are described herein individuallybut any suitable combination of these data types may be used to identifythe onset of the symptom. One or more of the movement data, hormoneactivity, kinematic scores, cadence of movement signals, gait report,movement score from a comparison using a baseline symptom profile, imagedata representative of a user's change in posture, data representativeof a measure of fatigue, or context information may be a dimension of afeature vector. For example, the symptom identifier module 224 generatesa feature vector that combines movement data, hormone activity, andcontext information as features in the vector for input into amachine-learned model that is trained on feature vectors of the threecorresponding activity data types measured when the user is experiencinga symptom of a physical condition. The symptom identifier module 224 mayapply weights to generating the feature vector. For example, if theGPS-enabled device has been providing erroneous GPS traces, the GPSlocation used in the context information may be inaccurate and thus,receive a smaller weight than activity data types that have been morereliable such as, for example, movement data measured by IMU's worn bythe user. The symptom identifier module 224 may adjust the weights basedon user feedback of the corresponding applied actuation instruction.

The dosing control module 225 determines actuation instructions to applythrough the dosing 202. The dosing control module 225 may be triggeredby the symptom identifier module 224 such that it determines whichactuation instruction to apply in response to an identified onset of asymptom by the module 224. The dosing control module 225 may determineone or more actuation instructions to apply, where each instruction hasa corresponding type. For example, the module 225 may determine to applya biofeedback actuation instruction and determine an actuationinstruction for adjusting a chemical stimulus administration (e.g.,titration of levodopa). The dosing control module 225 may determinewhich actuation instruction of the instructions within the actuationinstruction database 221 to apply depending on the identified onset ofthe symptom (e.g., the symptom and characteristics thereof).

Prior to determining a modification to the administration of a chemicalstimulus, the dosing control module 225 may identify the chemicalstimulus administered to a user to treat a physical condition of a user.The administration of the chemical stimulus, which may be a medicalprescription, may be characterized by an amount of a medication or atime at which the medication is to be taken. The module 225 may identifythe chemical stimulus by querying the user profile database 222 for alist of chemical stimulus taken by the user. In some embodiments, thesymptom identifier module 224 may identify which physical condition'ssymptom, the onset of which is or is about to occur, and provide theidentified symptom and physical condition to the dosing control module225. The user profile database 222 may be queried by the symptom orphysical condition to identify which chemical stimulus is being taken totreat the condition. In some embodiments, the dosing control module 225identifies the chemical stimulus based on a user's specification of aparticular physical condition for which they are using the symptomintervention assembly 110, and the module 225 is identifies the stimulusbased on the user's specification.

The dosing control module 225 can determine a modification to theadministration of a chemical stimulus. Modifications can includeincreasing or decreasing the amount of a chemical stimulus administered(e.g., titrated) or changing the time at which the chemical stimulus isadministered. In some embodiments, the dosing control module 225 maydetermine the modification based on an “on” or “off” period of thechemical stimulus. A patient using a chemical stimulus to treat theirphysical condition may experience “on” periods when the stimulus iseffective and “off” periods when the stimulus is not working as well andsymptoms of the physical condition begin to remerge. For example, themodule 225 determines an “on” time duration of the administration of thechemical stimulus, where the “on” time duration begins at a time whenthe chemical stimulus is administered and ends at an onset of a symptomafter that time. This onset may be identified by the symptom identifiermodule 224. The module 225 can determine an “off” time duration of theadministration of the chemical stimulus, where the “off” time durationbegins at an onset of the symptom (e.g., the onset at the end of an “on”period) and ends at a time that the chemical stimulus is administeredagain.

The dosing control module 225 may compare the “on” and “off” durationsto determine how to modify the administration of the chemical stimulus.For example, in response to determining that the “off” time duration isgreater than the “on” time duration, the module 225 may determine tomodify the timing of a dose of levodopa to be earlier than previouslyscheduled. To determine an amount by which the dosage or timing of thechemical stimulus's administered should be changed, the dosing controlmodule 225 may use a model associating differences in “on” and “off”periods to historical modifications of chemical stimulus by medicalprofessional. The model may be a machine-learned or statistical modelthat determines or interpolates a likely modification based on an inputdifference between “on” and “off” periods. In some embodiments, thedosing control module 225 may compare “on” or “off” periods to expected“on” or “off” periods and determine that a presently measured perioddeviates from the expected period over a threshold amount.

In some embodiments, the dosing control module 225 provides anotification that the administration of the chemical stimulus should bemodified, and may recommend a modification within the notification. Forexample, the dosing control module 225 may generate a notificationindicating that the dosage amount of levodopa is recommended to bedecreased by 10% and transmit it to the remote therapy system 140 overthe network 160 using the communications circuitry 204. In addition todetermining a modification of a chemical stimulus, the dosing controlmodule 225 may use the determined “on” and “off” periods for a chemicalstimulus to determine other actuation instructions such as applyingneuromodulation, biofeedback, FES, or a combination thereof. The dosingcontrol module 225 may use the dosing model 230 to determine therecommended modification.

The dosing control module 225 can use characteristics of a symptom todetermine how to modify an administration of a chemical stimulus. Thecharacteristics may include a severity of amplitude or frequency ofmonitored activity data. In some embodiments, the dosing control module225 can compare movement signals measured by the sensors 201 to signalsof a symptom profile, which is further described with reference to thesymptom identifier module 224, and use the comparison to determine themodification to the administration. For example, the currently monitoredmovement signals can show that a user is experiencing tremors that havean amplitude or frequency that deviates from those reflected in theirsymptom profile for their tremors, and the dosing control module 225 maydetermine an amount by which the current tremors deviates from theprofile's. This deviation may represent the severity of the tremors. Inresponse to determining that the severity of the tremors as worsened(e.g., increased amplitude or frequency), the dosing control module 225may determine to increase the dosage or shorten the time between twoconsecutive doses of the chemical stimulus. In response to determiningthat the severity of the tremors as improved (e.g., decreased amplitudeor frequency), the dosing control module 225 may determine to decreasethe dosage or increase the time between two consecutive doses of thechemical stimulus.

The dosing control module 225 may also determine various actuationinstructions in addition to chemical stimulus dosing instructions, suchas neuromodulation instructions. The dosing control module 225 maydetermine actuation instructions for applying neuromodulation. Thedosing control module 225 may determine stimulation parameters of theneuromodulation such as a frequency, pulse width, or amplitude of thestimulation signals. The electrodes placed at the user's brain may beconfigurable such that the dosing control module 225 can determine whichelectrodes should serve as a cathode, anode, or be disconnected (i.e.,not receiving or transmitting electrical stimulation at the brain). Thedosing control module 225 may determine to depolarize neurons of auser's brain by determining which of the configurable neuromodulationelectrodes should operate as a cathode. To hyperpolarize neurons of theuser's brain, the dosing control module 225 may determine which of theconfigurable neuromodulation electrodes should operate as an anode.

The dosing control module 225 may use characteristics of a symptom todetermine neuromodulation parameters to apply. Characteristics of theidentified symptom onset may include an acceleration or speed at whichthe user's limb shake during a tremor, a deceleration of leg movementover time related to slowing gait, an increase in knee joint anglerelated to crouch gait, or any suitable quantifiable parameter of asymptom. The dosing control module 225 may use characteristics of asymptom and a history of previous neuromodulation parameters to identifya neuromodulation operation to mitigate the identified symptom orsymptom onset. For example, the module 225 may determine an amplitude ofIMU signals tracking the acceleration of a user's tremors at a hand. Themodule 225 may determine the amplitude is similar to a previouslydetected amplitude that is associated with a historical neuromodulationoperation having a particular stimulation signal (e.g., frequency, pulsewidth, amplitude) and electrode configuration (e.g., which electrodesfunction as anodes, cathodes, or are disconnected). The historicalneuromodulation operations or feedback thereof may be characteristics ofthe user.

The dosing control module 225 may apply the dosing model 230 tocharacteristics of an identified symptom onset to determine aneuromodulation operation. In some embodiments, the dosing controlmodule 225 may estimate parameters of a neuromodulation operation (e.g.,interpolate an amplitude or frequency of previously applied electricalsignals) to apply and intervene with the identified symptom. In someembodiments, the module 225 may also determine whether the user providedpositive feedback or previously monitored movement of assisted movementwith the historical neuromodulation indicated effective symptomintervention.

The dosing control module 225 may apply the neuromodulation operationthrough a wearable neuromodulation system that includes electrodescoupled to the user, where the wearable neuromodulation system caninclude an implanted device with electrodes contacting the user's brainand a controller wired to the electrodes. In some embodiments, thewearable neuromodulation system is a device external to the user withelectrode contacts contacting the user's skin and configured to applyneuromodulation to neurons without penetrating the skin (e.g., contactsneurons at the user's leg).

In some embodiments, the dosing control module 225 uses a change in afrequency at which the onset of a symptom is identified to determine theactuation instruction to apply. The change in symptom frequency may bedetermined using the onsets identified by the symptom identifier module224. Based on the changes in symptom frequency, the module 225 candetermine electrical stimulation parameters for neuromodulation or aconfiguration of electrodes providing the neuromodulation. For example,the dosing control module 225 can determine to decrease the frequency ofelectrical stimulation signal applied to the user's neurons (e.g., whena decrease in the frequency is associated with a decrease in theoccurrence of the symptom). In another example, the dosing controlmodule 225 can determine a particular combination of neuromodulationelectrodes that should serve as cathodes, anodes, or be disconnected,where the particular combination is determined to be used responsive toa particular change in symptom frequency (e.g., when the frequencyincreases).

The dosing control module 225 may determine actuation instructions forapplying biofeedback. The dosing control module may determine a type ofbiofeedback to apply (e.g., audio, visual, or haptic). The dosingcontrol module may determine where to apply the biofeedback. Forexample, the user may be using two or more wearable devices that includevibrating mechanisms of the dosing 202 through which the symptomintervention assembly 110 can apply haptic biofeedback. The dosingcontrol module 225 may determine which of the wearable devices toactivate vibrations from (e.g., at the leg to help with a user's legs orat the arm to help promote balanced arm swings while walking). In thisway, the dosing control module 225 can provide biofeedback to the userthat includes sensory cues to promote a neurotypical movement in theuser responsive to determining that the user is experiencing a symptomof their physical condition.

The dosing control module 225 may determine one or more actuationinstructions to apply based on conditions for applying the one or moreof the actuation instructions. The conditions may be based on theactivity data used to identify the onset of the symptom. The conditionsmay include the type of movement that the user is performing, the user'slocation, heart rate, intended movement (e.g., based on measured EMGsignals), time of day, or user's schedule of events. In someembodiments, the actuation instruction database 221 also stores rules orconditions for the dosing control module 225 to determine whichactuation instructions to apply. For example, the dosing control module225 may determine that the user is at a concert, according toinformation provided on a calendar application on the user device 150,and determine that biofeedback of audio guidance for walking isinappropriate to apply due to the volume of the event drowning out thevolume of the audio guidance. Instead, the module 225 may determine toapply neuromodulation or FES. The conditions may be optimized based onuser feedback. For example, in response to the user providing a measureof low approval with biofeedback being provided at a certain time of dayor location, the dosing control module 225 may reduce the frequency atwhich biofeedback is provided at that time or location.

The GUI module 226 generates for display GUIs through which a user canmanage the functions of the symptom intervention assembly 110. Forexample, a user can provide feedback of applied actuation instructionsor control the actuation instructions performed by the symptomintervention assembly 110 to intervene with a symptom. A GUI may begenerated on a user device coupled to the symptom intervention assembly110. The GUI module 226 may display information describing theintervention such as properties of an applied neuromodulation signal andthrough which electrodes the signal is applied (e.g., the identificationnumbers of the electrodes serving as the anodes and cathodes). The GUImodule 226 may provide an interactive user interface that includesvarious buttons, toggles, menus, etc. through which a user can managethe intervention determined or applied by the symptom interventionassembly 110. FIGS. 5-6 show example GUIs that may be generated by theGUI module 226.

The model training engine 227 trains a model to identify an onset of asymptom of a physical condition based on activity data. The modeltraining engine 227 may train a machine learning model in multiplestages. In a first stage, the model training engine 227 may use activitydata (e.g., movement signals, hormone activity, chemical stimulusadministration data) collected across one or more users (e.g., apopulation of Parkinson's disease patients) to train a machine learningmodel. This data from a population of users may be referred to as“general data” or “generalized data.” The model training engine 227 maylabel the general data with a label representative of whether thegeneralized data coincided with the occurrence of an onset of a symptomof a physical condition. The model training engine 227 creates a firsttraining set based on the labeled general data. The model trainingengine 227 trains a machine learning model (e.g., the general symptomidentification model 228), using the first training set, to identify theonset of a symptom. In some embodiments, the machine learning model isconfigured to receive, as an input, activity data (e.g., from thesensors 201) or a feature vector of activity data (e.g., determined bythe symptom identifier module 224), and output a confidence scoreassociated with the identification of the onset of the symptom.

In a second stage of training, the model training engine 227 can useuser-specific activity data (e.g., collected by the sensors 201). Themodel training engine 227 creates a second training set based onpreviously identified symptom onsets (e.g., by the trained generalsymptom identification model 228) and the data representative ofmeasured movement collected from the user of the symptom interventionassembly 110 (i.e., user-specific data). The identified symptom onsets,depending on the success of the corresponding applied actuation (e.g.,as indicated by user feedback), may serve as labels for theuser-specific data. If a previously determined actuation instructionresulted in symptom intervention that was effective or comfortable, themodel training engine 227 may create the second training set thatincludes user-specific data labeled to indicate the symptom wascorrectly identified in the activity data. The model training engine 227then re-trains the machine learning model using the second training setsuch that the machine learning model is customized to the user'sactivity. For example, the model training engine 227 may re-train thegeneral symptom identification model 228 such that the re-trained modelis the user-specific symptom identification model 229. The dosing model230 may also be trained by the model training engine 227 similarly instages. A first stage may use dosing data from a general population ofusers and the second stage may use user feedback to create a secondtraining set for retraining the dosing model 230.

To create a training set, the model training engine 227 may determineone or more feature vectors associated with measured activity data(e.g., a feature vector representing a combination of movement signals,hormone activity, and chemical stimulus administration). For example,the model training engine 227 may determine a feature vectorcharacterizing movement signals and hormone activity associated with anonset of a tremor of Parkinson's disease.

In some embodiments, the model training engine 227 may retrain amachine-learned model using feedback of a modification to a chemicalstimulus administration determined by the dosing control module 225. Themodel training engine 227 receives feedback of the determinedmodification indicating a measure of approval that the user has with thedetermined modification. For example, the user may provide feedbackthrough a GUI, where the feedback is an approval or rejection of thedetermined modification. The model training engine 227 may modify anassociation between the identified onset of the symptom of the physicalcondition and the monitored movement signals that were used to identifythe onset. For example, in response to the user providing a measure ofapproval indicating disapproval, the model training engine 227 reduces aweight applied to signals from the same source as the monitored movementsignal. If the monitored movement signals were collected from a footpressure sensor, the model training engine 227 may reduce a weight ofpressure signals from the foot pressure sensor, where the weight is usedto generate a feature vector, which itself can be used to train amachine-learned model. When the modified association including thereduced weight is used to retrain a machine-learned model, the modeltraining engine 227 may cause the likelihood of subsequent similarsymptom identifications based on foot pressure sensor data to decrease.

In response to the user providing a measure of approval indicatingapproval of the modification to the chemical stimulus administration,the engine 227 may increase a weight applied to signals from the samesource as the monitored movement signal. In addition or alternative toan association between the identified symptom onset and the monitoredmovement signals being adjusted, an association between the identifiedsymptom and the determined actuation (e.g., the modification to thechemical stimulus administration) may also be modified. Examples ofmeasures of approval may include direct feedback such as a rating of theapplied actuation or indirect feedback such as a request to modify theactuation (e.g., a request to stop the actuation), which may indicatedisapproval with the applied actuation.

The general symptom identification model 228 is configured to identifyan onset of a symptom of a physical condition. There may be generalmodels for respective symptoms or physical conditions, depending on thetraining data used to train the general models. For example, generalmodels can be maintained for each of a tremor, FOG, and bradykinesia ofParkinson's disease. The general symptom identification model 228receives, as input, data representing the activity measured by thesymptom intervention assembly 110 and outputs an identification of orconfidence score associated with an identification of an onset of asymptom of a physical condition. The general symptom identificationmodel 228 may receive activity data collected across a population ofusers of the symptom intervention assembly 110 experiencing a particularsymptom of a physical condition.

The user-specific symptom identification model 229 can be trained by themodel training engine 227 using activity data collected from the sensors201 such that data for training is specific to the user of the symptomintervention assembly 110. The model 229 may be obtained by re-trainingthe general symptom identification model 228. Because the model 229 istrained on user-specific activity data, the model 229 enables thesymptom intervention assembly 110 to be personalized to the user andimprove its accuracy in identifying onsets of symptoms as experienced bythe user, which in turn improves the determined actuation (e.g., themodification of a chemical stimulus administration). The user-specificsymptom identification model 229 may, similar to the general symptomidentification model 228, be configured to identify, for varioussymptoms or physical conditions, a corresponding onset.

In some embodiments, the symptom intervention system 220 includes amachine-learned model (e.g., the dosing model 230) for determining amodification to a chemical stimulus administration. The model trainingengine 227 may create training data based on historical modifications tostimulus administrations, which may include prescription or titrationchanges that medical professionals have made, an anonymized profile of apatient's symptom history and physical characteristics, or any suitableinformation correlating a modification to a change in symptomsexperienced over time. The model training engine 227 may train thedosing model 230 using the training data to output a recommendedmodification to a chemical stimulus administration based on a user'ssymptom progress over time. The symptom identifier module 224 may trackthe user's symptom progress and store relevant data in the user profiledatabase 222.

The relevant data indicative of the user's symptom progress may includea change in frequency of identifying the symptom, a change in severityof the symptom (e.g., the amplitude of the movement signals of a user'stremors are increasing), the appearance of a symptom previously notaffecting the user, the disappearance of a symptom affecting the user,the appearance of an existing symptom under conditions previously notassociated with the existing symptom (e.g., the user is experiencing FOGat a time of day when they had previously not experienced it), or anysuitable characteristic of a change in the user's symptoms. In someembodiments, the dosing control module 225 may apply the modificationdetermined by the machine-learned model using the dosing 202. Forexample, the determined modification includes a change to the titrationtiming and dosage of levodopa, which the dosing control module 225 mayimplement by controlling a portable pump that administers levodopa or asimilar stimulus to the user.

Machine learning models of the symptom intervention system 220 may usevarious machine learning techniques such as linear support vectormachine (linear SVM), boosting for other algorithms (e.g., AdaBoost),neural networks, logistic regression, naive Bayes, memory-basedlearning, random forests, bagged trees, decision trees, boosted trees,boosted stumps, a supervised or unsupervised learning algorithm, or anysuitable combination thereof. The machine learning models may haveaccess to a broader set of features on which to train. For example, themodels may use physiological simulation as a component for identifyingan onset of a symptom.

Alternatively, the models described herein may be a statistical modelgenerated based on previously measured activity data and correspondingsymptom onset identified. The statistical model may be configured toidentify an onset of a symptom that is most likely to correspond tomeasured activity data. The models described herein may also be arules-based decision model that identifies an onset of a symptom basedon a test of various rules or conditions such as whether measuredmovement signals of the activity data deviates from an expected movementprofile by over a threshold deviation, if the user is at a particularlocation or not, or any other suitable test for identifying an onset ofa symptom based on evaluable conditions.

Although the symptom intervention system 220 is depicted as being acomponent of the symptom intervention assembly 110, the remote symptomintervention system 120 may provide the same or similar functionalitysuch that the processing burden is shifted from the MCU 205 toprocessors local to the remote server hosting the remote symptomintervention system 120. The data captured by the sensors 201 may becommunicated via the communications circuitry 204 to the remote symptomintervention system 120. For example, kinetic signals measured by theIMU sensors of the sensors 201 are stored in a Secure Digital (SD)memory card at a wearable device of the symptom intervention assembly110 (e.g., components of the assembly 110 integrated into a knee wrap).The symptom intervention system 220 can upload data from the SD card toa remote database (e.g., the database 130), and the remote symptomintervention system 120 accesses the database 130 to identify an onsetof a symptom and provide actuation instructions to the dosing 202 overthe network 160. The remote symptom intervention system 120 may behosted on a computing device such as a smartphone or a tablet, where thecomputing device can be communicatively coupled to the symptomintervention assembly 110 via the network 160.

FIG. 3 is a block diagram of a feedback loop 300 for optimizing symptomintervention by a symptom intervention assembly, in accordance with atleast one embodiment. The feedback loop 300 is a closed-loop system thatminimizes a difference between user movement assisted by the symptomintervention assembly and a target movement (e.g., a neurotypicalmovement). The feedback loop 300 may be performed by a symptomintervention system 320 of a symptom intervention assembly. For example,the symptom intervention system 320 monitors activity data, determinesan actuation for symptom intervention based on the monitored activitydata, monitors activity data capturing the user's movement assisted byapplying the determined actuation (i.e., the monitored data serves asfeedback), and adjusts a subsequently applied actuation based on thefeedback. The feedback loop includes sensors 310, the symptomintervention system 320, and dosing 340. The symptom intervention system320 may be the same or similar to the symptom intervention system 220 ofFIG. 2. The system 320 includes a symptom identifier module 324, auser-specific symptom identification model 329, a dosing model 330, amodel training engine 323, and a dosing control module 325. The feedbackloop 300 may have alternative configurations than shown in FIG. 3,including different, fewer, or additional components.

The optimization of symptom intervention may begin with an initialapplication of actuation, which is determined by the symptomintervention system 320 using activity data monitored through thesensors 310. The sensors 310 measure activity data such as IMU signals,EMG signals, image data, heart rate, and foot pressure signals. Thesymptom identifier module 324 may determine characteristics of fatigue,tremors, arm swing, movement rigidity, a posture or change therein, or agait. The module 324 may also determine “on” and “off” periods of achemical stimulus, a movement cadence, kinematic metric score, or a gaitreport based on the measured activity data from the sensors 310. Thesymptom identifier module 324 may apply the user-specific identificationmodel 329 to one or more of the measured activity data from the sensors310 or derived activity data from the module 324. The user-specificidentification model 329 and the dosing model 330 may be amachine-learned model trained by the model training engine 323. Themodel 329 can output a confidence score for the identification of anonset of a symptom, and in response to the confidence score meeting orexceeding a threshold confidence score, the symptom identifier module324 may trigger the dosing control module 325 to determine an actuationinstruction. The module 325 may use the dosing module 330 to determinean actuation instruction corresponding to the identified symptom. Asymptom intervention system's determination of an actuation instructionfor symptom intervention based on activity data is described in furtherdetail in the description of FIG. 2.

The dosing control module 325 may be triggered by the symptom identifiermodule 324 after the module 324 determines that a symptom onset isoccurring or will occur soon (e.g., after a time window, such as the“on” period of a chemical stimulus, passes). The dosing control module325 uses the dosing model 330 to determine an actuation instructionbased on the identified symptom onset, and provides the actuationinstruction to the dosing 340. The output of actuators 340, as depictedin FIG. 3, is the user's movement as assisted by the actuationinstruction. For example, the output of the dosing 340 could be a user'sgait with the assistance of neuromodulation specified by the actuationinstruction determined by the dosing control module 325. In anotherexample, the output of the dosing 340 could be a user's still hands(i.e., lacking tremors) after the user's body has metabolized a modifieddose of levodopa, where the modification is determined by the module 325and applied by the dosing 340. The assisted movement may be monitored bythe sensors 310, as depicted by the arrow connecting the dosing 340 tothe sensors 310. The monitored assisted movement may be used as feedbackto retrain the user-specific symptom identification model 329. The inputof this feedback is depicted as an arrow between the sensors 310 and themodel training engine 323. The user may also provide feedback of theassisted movement, which is provided to the symptom intervention system320. For example, a user provides an approval rating of the assistedmovement using a GUI generated on a user device that is communicativelycoupled to the symptom intervention assembly and thus, to the symptomintervention system 320. The user feedback is used by the model trainingengine 323 of the symptom intervention system 320 to retrain the model329.

The feedback is used to retrain the user-specific symptom identificationmodel 329. The model training engine 323 may access the actuationinstruction associated with the feedback received and score the appliedactuation instruction based on the level of approval of the symptomintervention or assisted movement. The engine 323 may access theinstruction from the dosing control module 325 as the instruction isdetermined or from a database storing previously applied actuationinstructions (e.g., the actuation instruction database 221). The levelof approval may be proportional to an amount by which an assistedmovement deviates from a target movement, and the score may beproportional to the level of approval. Using the score, the modeltraining engine 323 may create a training set of labeled data. Activitydata can be labeled with an actuation instruction depending on thedetermined score. For example, if the score of the assisted movement islow due to low level of approval, the model training engine 323 maycreate a negative sample using the applied actuation as a label to themeasured movement that resulted in the unsatisfactory actuation to beapplied. In another example, if the score of the stimulated movement ishigh due to a high level of approval, the model training engine 323 maysimilarly create a positive sample. The model training engine 323 canuse the positive and negative samples to re-train the user-specificsymptom identification model 329 to refine the symptom interventionbased on the user's body and behavior. Accordingly, feedback frommonitored assisted movement or provided by the user through an interfaceallows the symptom intervention system to personalize and optimize thedetermined actuation and symptom intervention to the user.

FIG. 4 shows a configuration 400 of symptom intervention assemblycomponents on or near a user's body, in accordance with at least oneembodiment. The configuration 400 includes sensors to monitor activitydata such as movement sensors 410-413, pressure sensors 420 and 421, anda camera 440. The configuration 400 includes actuators to intervene withsymptoms of the user's physical condition such as neuromodulationelectrodes 450 and a stimulation titration 460.

The symptom intervention assembly (e.g., the assembly 110 of FIGS. 1 and2) monitors a user's movement through the movement sensors 410-413,which may include IMUs and EMG sensors located at the user's limbs. Forexample, movement sensors 410 and 411 are IMUs embedded within glovesworn by the user and provide movement signals indicative of the user'sarm swings during a gait cycle (e.g., tracking the reduced arm swing ofParkinson's patients). The movement sensors 412 and 413 may be IMUsembedded within leggings worn by the user and provide movement signalsindicative of the user's gait (e.g., tracking the symmetry of left andright leg steps). The pressure sensors 420 and 421 may be foot pressuresensors embedded within socks or the soles of shoes and provide pressuresignals indicative of the user's gait (e.g., a frequency of steps or thestrength of the step).

The camera 440 may be a camera installed within the user's home or at amedical professional's office to capture images or videos of the user'smovement or changes in posture. The camera 440 may provide the captureddata to a processor of the symptom intervention assembly (e.g., the MCU205) for the symptom intervention system to perform image processing onthe captured data. The captured data may depict movements of a gait likea toe-off or mid-swing or a user's posture. A symptom identifier moduleof the symptom intervention system may identify a symptom of a physicalcondition, such as a change in the user's posture (e.g., stoopedshoulders of a user having Parkinson's disease), from the captured data.

The symptom intervention assembly components depicted in configuration400 include actuators in both the neuromodulation electrodes 450 and thestimulus titration 460. The neuromodulation electrodes 450 are locatedat the user's brain and may be communicatively coupled to a controllerthat is implanted within the user. This controller may host the symptomintervention system or be communicatively coupled to the symptomintervention system such that it may receive actuation instructions froma dosing control module of the system. For example, the dosing controlmodule determines to hyperpolarize neurons at the user's brain toheighten the relaxing of the user's muscles (e.g., to reduce rigidity inthe user's arms or legs due to Parkinson's disease) and determines oneor more electrodes of the neuromodulation electrodes 450 to serve asanodes to stimulate the muscle relaxation.

The symptom intervention assembly may also intervene with symptoms of auser's physical conditions by modifying a chemical stimulus'sadministration. The stimulus titration 460 may include a delivery systemfor a chemical stimulus such as levodopa, baclofen, carbidopa, or anyother automatically administrable chemical stimulus for treating aphysical condition that affects a user's movement. In one example, adelivery system of the titration 460 includes a pump that provides thechemical stimulus to the user through a tube into the user's body. Thepump may include communications circuitry that enables it to receiveactuation instructions from a symptom intervention system and aprocessor execute the instructions. In some embodiments, the deliverysystem includes a processor that hosts the symptom intervention system.An example actuation instruction that the stimulus titration 460 mayexecute is to modify the dose of levodopa to be 10% less than thecurrent dose or to be delivered a determined amount of time earlier thanscheduled.

In some embodiments, the symptom intervention system determines one ormore actuation types to apply depending on the symptom identified. Asdescribed in the description of the dosing control module 225 of FIG. 2,the system may determine actuation instructions according to arules-based system where an identified symptom or characteristic of theidentified symptom corresponds to one or more actuation instructions.For example, the symptom intervention system may determine to activateboth the neuromodulation electrodes 450 and the stimulus titration 460in response to detecting a user's quality of gait has decreased to apredetermined quality (e.g., the kinetic signals deviate, on average,from a target signal beyond a threshold amplitude). Further, althoughnot depicted, the configuration 400 may include actuators to applybiofeedback such as speakers, displays, or haptic mechanisms.Accordingly, a symptom intervention assembly, which may have theconfiguration 400, may help a user monitor for onsets of symptoms oftheir physical conditions in various manners and apply one or moreactuation instructions to intervene with identified onsets.

User Interfaces for the Symptom Intervention System

FIG. 5 depicts a GUI for managing chemical stimulus administrationmodifications determined by a symptom intervention assembly, inaccordance with at least one embodiment. The GUI may be displayed on auser device (e.g., the user device 150). The GUI includes a heading 510,a modification panel 520, and user feedback buttons 530. The GUI shows adetermined modification to a user's current chemical stimulusadministration (e.g., medical prescription of levodopa). A GUI module ofa symptom intervention system (e.g., the GUI module 226) may retrievethe determined actuation instruction, as determined by the dosingcontrol module 225, and provide it for display at the user device 150.The heading 510 indicates that the GUI is used to manage an actuation ofchemical stimulus administration. As shown in the panel 520, theactuation instruction includes a proposed modification of the titrationby −10% in dose amount and reducing the number of times the stimulus istaken by one time. A user of the symptom intervention assembly mayselect one of the user feedback buttons 530 to approve of themodification to their titration or deny the modification. In response tothe user selecting one of the user feedback buttons 530, the user device150 may provide the selection to the symptom intervention system toserve as instructions to either apply or not apply the modificationthrough actuators or serve as feedback to retrain or update a model usedto determine an onset of the symptom (e.g., the symptom identificationmodels 228 or 229) or actuation instructions to apply (e.g., the dosingmodel 230).

FIG. 6 depicts a GUI for managing neuromodulation applied by a symptomintervention assembly, in accordance with at least one embodiment. TheGUI may be displayed on a user device (e.g., the user device 150). TheGUI includes a heading 610, an actuation summary panel 620, userfeedback toggle 630, and an actuation termination button 640. The GUIshows a determined modification to a user's current chemical stimulusadministration (e.g., medical prescription of levodopa). The GUIprovides information about the actuation applied by the symptomintervention assembly and enables the user to manage the appliedactuation. For example, the user can provide feedback of the actuationthrough the user feedback toggle 630 or stop the actuation through thebutton 640. The heading 610 indicates that the GUI is used to manage anactuation of neuromodulation. The panel 620 shows parameters of theneuromodulation such as a frequency, pulse width, and amplitude of theelectrical signal. Further, the panel 620 provides information regardingthe neuromodulation electrodes and their roles (e.g., anode, cathode, ordisconnected), which may be indicated by different colors (or shadingstyles).

The user may provide direct or indirect feedback of the appliedneuromodulation summarized in the panel 620. In one example, the usermay use the toggle 630 to indicate a level of approval of the appliedstimulation based on the comfort with or effectiveness of theneuromodulation. The level of approval may be on a sliding scale whoseuser-selected value is provided to the symptom intervention system bythe user device 150 on which the GUI is displayed. This type of feedbackmay be direct feedback: user-provided information whose primary role isas feedback of the symptom intervention. In another example, the usermay stop the actuation instruction being applied by the symptomintervention assembly using the button 640. This type of feedback may beindirect feedback: user-provided information whose primary role is torequest a change in the operation of the symptom intervention assemblyand whose secondary role is feedback of the symptom intervention.

The user-provided feedback through the GUIs depicted in FIGS. 5 and 6can be stored in a user profile database (e.g., the user profiledatabase 222) of the symptom intervention system. The user profiledatabase 222 may store the user's chosen actuation modification and linkthe modification to the identified symptom or the user activity thatpredicated the applied actuation such that subsequent interventions areoptimized to the user's modification (e.g., the actuation instruction isnot applied for the identified symptom going forward).

Processes for Movement Assistance Using the Symptom Intervention System

FIG. 7 is a flowchart illustrating a process 700 for determining amodification to an upcoming administration of a chemical stimulus, inaccordance with at least one embodiment. The symptom intervention system220 can perform operations of the process 700 in parallel or indifferent orders, or perform different steps. For example, the symptomintervention system 220 may monitor 702 movement signals whileidentifying 701 a chemical stimulus. In another example, the system 220can also monitor movement signals after the chemical stimulus is appliedsuch that the process 700 may include a feedback loop to adjustsubsequent administration modifications based on the applied stimulus.In this way, the process 700 may adjust and optimize the stimulusadministration to the user's movements.

The symptom intervention system 220 identifies 701 a chemical stimulusadministered to a user to treat a physical condition of a user, whereinan upcoming administration of the chemical stimulus is characterized byat least one of a dose and a time to administer the chemical stimulus.For example, the symptom identifier module 224 or the dosing controlmodule 225 may query the user profile database 222 to identify 701 thatthe user is taking levodopa, the dose of levodopa being taken, and atwhich times during the day that the doses are taken. The levodopa may betitrated the user throughout the day. For example, a larger dose may beadministered in the morning and gradually smaller doses are administeredto the user every couple of hours until some time in the evening. Thesystem 220 may determine the current time of day and identify that,based on the current time of day, an upcoming administration of levodopais to be administered at a dose of 50 mg at 14:00. The system 220 maynotify the user (e.g., through the user device 150) at 14:00 to take apill for levodopa. Alternatively, the administration may be automatedusing a pump and a gel form of levodopa.

The symptom intervention system 220 monitors 702 movement signalsrepresentative of movement of the user. The symptom identifier module224 may receive kinematic signals measured using IMUs of the sensors201, where the IMUs are located at the user's legs such that thereceived kinematic signals reflect the user's gait. The kinematicsignals may show that the acceleration of one of the user's legs duringa gait cycle is decreasing, which may indicate an upcoming onset asymptom of Parkinson's disease (e.g., imbalanced gait or shuffling).These kinematic signals may also indicate that the “on” period of thelast dose of levodopa taken is reaching its end, and that an “off”period is soon to set in.

The symptom intervention system 220 determines 703, using amachine-learned model configured to identify an onset of a symptom ofthe physical condition based on the monitored movement signals, whetherto modify the upcoming administration of the chemical stimulus. Thesymptom identifier module 224 may apply the user-specific symptomidentification model 229 to the monitored movement signals. The model229 may be trained using kinematic signals representing the user's gaitsimilar to the monitored signals (e.g., using IMUs located at the samelocation as the IMUs monitoring the user), where the kinematic signalsrepresent the gait when the user is experiencing, or soon to experience,a symptom and is labeled with the symptom. The model training engine 227may perform this training. The output of the machine-learned model 229may be an identification of the symptom (e.g., an imbalanced gait) and aconfidence of the identification. For example, the model 229 determineswith 70% confidence that the monitored 702 movement signals indicate anonset of an imbalanced gait.

The symptom intervention system 220 determines 704 whether to modify theupcoming administration of the chemical stimulus. The symptom identifiermodule 224 may use a confidence score associated with themachine-learned model's identification of the onset of the symptom todetermine 704 whether to modify the upcoming administration. Forexample, the symptom identifier module 224 uses a predefined thresholdconfidence score of 70%, where a confidence score meeting or exceedingthat threshold warrants modification to an upcoming administration. Anidentification by the machine-learned model 229 of an onset ofimbalanced gait with a 70% confidence may thus cause the symptomidentifier module 224 to trigger the dosing control module 225 todetermine a modification. Otherwise, if the confidence score does notmeet or exceed the threshold confidence score, the process 700 mayreturn monitoring 702 movement signals representative of movement of theuser. These subsequently monitored movement signals can be used todetermine whether an onset of a symptom is likely to occur and whetheran upcoming administration should be modified.

The symptom intervention system 220 determines 705 a modification to thedose or the time associated with the upcoming administration of thechemical stimulus. The dosing control module 225 may determine to modifya dose of the upcoming administration based on the monitored 702movement signals. For example, the module 225 may compare the gaitmovement characterized by the monitored signals to a target movement,which may be characterized by previously measured kinematic signals, anddetermine a measure of the deviation from the target movement. Usingthis deviation, the module 225 may determine an amount by which the doseshould increase or decrease. For example, the module 225 may accesshistorical records of dose modifications (e.g., as determined manuallyby medical professionals or automatically by the symptom interventionassembly) to determine a recommended modification that is similar toprevious modifications for similar deviations from a target movement.

The dosing control module 225 may determine to modify a time associatedwith the upcoming administration based on the monitored 702 movementsignals. For example, the module 225 may use “on” and “off” periods of achemical stimulus to determine how the time should be modified. Themodule 225 may determine a time at which an “off” time duration oflevodopa will begin. The symptom intervention system may accesshistorical records of kinematic signals mapped to corresponding timesduring “on” or “off” periods of levodopa, and compare the monitoredmovement signals to the historical records to determine the time atwhich the “off” period will begin. The dosing control module 225 mayidentify a stimulus metabolism period that indicates a time periodbetween the intake of a chemical stimulus and a peak efficacy of thechemical stimulus. This stimulus metabolism may be manually provided(e.g., by a medical professional) or estimated by the symptomintervention system based on hormone activities within the user's body.The module 225 may update the administration time of levodopa to beearlier than the time at which the “off” period will begin by thestimulus metabolism period. For example, if the original upcoming timeto take levodopa was 14:00, the module 225 determines that an “off”period will start at 13:55 and the stimulus metabolism period is 15minutes long, the module 225 may automatically administer, or notify theuser to take their next dose of levodopa, at 13:40 instead of at 14:00.

The symptom intervention system 220 applies 706 the chemical stimulus tothe user based on the determined modification. The dosing control module225 may provide actuation instructions to the dosing 202 to apply 706the chemical stimulus at the modified time or dose. For example, themodule 225 may provide actuation instructions that a levodopa pumpadminister the next dose of levodopa at 13:40 instead of at 14:00, thusapplying 706 the levodopa to the user based on the determinedadministration time modification. The process 700 may return tomonitoring 702 movement signals to continue optimizing symptomintervention over time.

FIG. 8 is a flowchart illustrating a process 800 for applyingneuromodulation, in accordance with at least one embodiment. The symptomintervention system 220 monitors 801 movement signals representative ofmovement of a user. The symptom identifier module 224 may receivekinematic signals measured using IMUs and EMG signals measured using EMGsensors of the sensors 201. The IMUs and EMG sensors can be located atthe user's legs such that the received kinematic and EMG signals reflectthe user's gait or intention to step through their gait. The monitoredsignals may show signs of a physical condition's symptoms in the user'sgait. For example, fatigue is a symptom of Parkinson's, and may becaused by akinesia (i.e., difficulty starting a movement) or extrastrain on muscles caused by other symptoms in Parkinson's disease suchas muscle stiffness or tremors. The monitored 801 movement may indicatethe onset of fatigue in a slowness or weakness in movement through thegait. For example, IMU signals show that the acceleration of one of theuser's legs during a gait cycle is decreasing. The EMG signals may showthe frequency of electroactivity is decreasing. The symptom identifiermodule 224 may identify both the decrease in acceleration and frequencyof electroactivity.

The symptom intervention system 220 determines 802, using amachine-learned model configured to identify an onset of a symptom of aphysical condition based the monitored movement signals, whether tomodify parameters of neuromodulation symptom intervention. The system220 may determine that the user is exhibiting a particular symptom ofthe symptoms of the physical condition, and in response to determiningthe particular symptom is being exhibited, determine to modifyneuromodulation parameters. A physical condition may have many symptoms.For example, Parkinson's disease symptoms include tremors, FOG,imbalanced gait, shuffling or slowed gait, fatigue, bradykinesia, andother symptoms related or unrelated to movement. The symptomintervention system 220 may use a machine-learned model to identify theonset of one or more of these symptoms, the number of which may dependon the way a machine-learned model is trained or the number of trainedmachine-learned models maintained by the symptom intervention system220. For example, the system 220 may train and apply a machine-learnedmodel for respective Parkinson's disease symptoms, where each model canbe trained on activity data that is labeled with the correspondingsymptom. The symptom identifier module 224 may apply the user-specificsymptom identification model to the monitored 801 EMG and IMU signals toidentify that an onset of fatigue is occurring. In another example, thesymptom identifier module 224 may apply the general symptomidentification model 228 to IMU signals monitored 801 at the user'shands to identify that an onset of a tremor is occurring.

The symptom intervention system 220 can determine whether the particularsymptom is a first symptom or a second symptom of the user's physicalcondition symptoms. A machine-learned model may output a confidencescore associated with the identification of an onset of a symptom, andthe symptom identifier module 224 may use the confidence score todetermine whether the identified onset is indeed an onset of thesymptom. For example, the symptom identifier module 224 compares aconfidence score associated with the identification of the onset offatigue by the user-specific symptom identification model 229 with athreshold confidence score to determine that the user is, with asufficiently high likelihood, experiencing the onset of fatigue. Themodule 224 may also apply another machine-learned model to the activitydata, where the other machine-learned model is trained to identify theonset of tremors, and reinforce, based on a confidence score output bythe other model, its determination that the user is experiencing theonset of fatigue rather than the onset of a tremor. In a second example,the symptom identifier module 224 may similarly determine that themonitored 801 IMU signals at the user's hands indicate the onset of atremor rather than fatigue. In these examples, the first symptomidentifiable by the module 224 is fatigue while the second symptom is atremor.

The symptom intervention system 220 determines 803 a modification toneuromodulation parameters, which can include at least one of afrequency, pulse width, amplitude, polarization, or duration of anelectrical signal. The system 220 can modify parameters to depolarize afirst plurality of neurons of the user if the system 220 determines theparticular symptom exhibited is a first symptom. Following an earlierexample, a first symptom of the user's condition is fatigue while asecond symptom is a tremor. Depolarizing a user's particular neuron orgroup of neurons may cause a corresponding muscle group to contract.Assisted contraction of the muscle may be helpful to perform motionssuch as walking. Accordingly, when the symptom identifier module 224determines that the user is or will experience the onset of fatigue thataffects their gait, the module 224 triggers the dosing control module225 to determine an appropriate actuation instruction to stimulateneuromodulation electrodes and contract muscles for the user's gait.

The dosing control module 225 may determine the appropriate actuationinstruction based on monitored EMG signals and rules mapping aconfiguration of neuromodulation electrodes to the stimulation of acorresponding muscle group. Examples of using EMG signals to determineelectrical stimulation (e.g., FES) may be found in U.S. patentapplication Ser. No. 17/113,058 and 17/113,059, filed Dec. 6, 2020,which are incorporated herein by reference. For example, the module 225may determine from monitored EMG signals that the user is intending toperform a toe-off in the gait cycle and in response, the module 225 usesa mapping of toe-off to a particular configuration of neuromodulationelectrodes to determine which neuromodulation electrodes are to beanodes, cathodes, or disconnected and the parameters (e.g., frequency,pulse width, and amplitude) of the neuromodulation signal appliedthrough the determined electrode configuration. In particular, themodule 225 may determine which of multiple configurable electrodesshould operate as a cathode to depolarize the appropriate neurons. Themodule 225 may determine the appropriate neuromodulation stimulation foreach movement within a gait cycle, thus helping the user contract theappropriate muscles while they walk.

The symptom intervention system 220 can determine 803 a modification toneuromodulation parameters that hyperpolarizes a second plurality ofneurons of the user if the system 220 determines the particular symptomexhibited is the second symptom. Hyperpolarizing a user's particularneuron or group of neurons may cause a corresponding muscle group torelax or achieve heightened relaxation. Assisted relaxation of themuscle may be helpful to reduce or prevent tremors, which arecharacterized by involuntary contractions of muscles. Following anearlier example, a first symptom of the user's condition is fatiguewhile a second symptom is a tremor. Accordingly, when the symptomidentifier module 224 determines that the user is or will experience theonset of a tremor, the module 224 triggers the dosing control module 225to determine an appropriate actuation instruction to stimulateneuromodulation electrodes and relax muscles to control the tremor. Forexample, the module 225 may determine from monitored IMU signals thatthe user has tremors of a particular severity (e.g., frequency ormagnitude of the tremors) and in response, the module 225 uses a mappingof the severity to a particular configuration of neuromodulationelectrodes and the parameters of the neuromodulation signal appliedthrough the determined electrode configuration. In particular, themodule 225 may determine which of multiple configurable electrodesshould operate as an anode to hyperpolarize the appropriate neurons.

The symptom intervention system 220 may apply 804 neuromodulationintervention to the user based on the determined modification. Forexample, the system 220 applies an electrical signal characterized bythe modified neuromodulation parameters to electrodes of the dosing 202.The electrodes may be proximate to neurons of the user (e.g., at thebrain or a muscle group such as a shank). The process 800 may return tomonitoring 801 movement signals to dynamically optimize the applicationof neuromodulation (e.g., when and how) to the user's movement.

Experimental Findings

FIG. 9 shows experimental findings 900 and 910 of the intervention ofdrop foot in two adult users by the symptom intervention assemblydescribed herein. Drop foot may primarily be a symptom of users who havepreviously suffered from a stroke, but can also affect users having CPor MS. Drop foot occurs during a gait where the foot does not return tozero degrees (i.e., the sole of the foot is flat or substantiallyparallel to a level ground), which may cause tripping and compromisetheir gait. A symptom intervention assembly measured the drop footthrough kinematic signals captured at sensors coupled to the user's foot(e.g., IMUs embedded in a user's shoe). The assembly can determine theonset of the drop foot based on the measured movement signals anddetermined to apply FES stimulation to intervene with the drop foot. Theresulting movement with assistance from the FES stimulation is shown inthe findings 900 and 910 along with the measured movement withoutassistance from the FES stimulation. The findings 900 and 910 show thatthe assembly improved metrics that measure the quality of a gait such asfoot angle at heel strike, loading response time (i.e., the time takenfor a foot to transition from heel strike to flat foot), and averagedorsiflexion in a swing. The dorsiflexion can be the direct causalresult of the FES stimulation (e.g., causing the foot to lift). In thegraphs showing the adult users' foot angles at heel strike, the FESactuation provided by the symptom intervention assembly was able tostimulate the foot to lift in its dorsiflexion and increase the footangle at heel strike. As shown in the graphs of the adult users' footangle over a full gait cycle, the FES actuation is able to produce agait that does not drop (i.e., front of feet pointing downward) with anangle magnitude as large as a gait without assistance. Further, the FESactuation is able to produce a gait that can return and stay at zerodegrees (e.g., at 20% through approximately 50% of the gait cycle) moreconsistently than the unassisted gait.

FIG. 10 shows experimental findings 1000 a and 1000 b of knee kinematicsaugmented with FES. The findings 1000 a and 1000 b were taken from a 10year-old child with primarily unilateral spastic CP. Her movements weremonitored with and without FES. The sensors and actuators of a symptomintervention assembly were positioned at each of her legs and thesensors measured kinematic signals from her gait cycle. Her right legshowed neurotypical movement while her left leg's movement was impactedby CP. She experienced the CP symptom of crouch gait, which ischaracterized by a deeper bend in the knee when walking. A symptomintervention assembly was able to apply FES to intervene with the crouchgait, decreasing the joint angle in the left leg so that it more closelymirrored her right leg.

Graph 1000 a shows her knee kinematics without FES applied. Kinematicsignal 1001 a of the graph 1000 a shows her right knee's flexion angleexhibiting neurotypical movement. Kinematic signal 1002a of the graph1000 a shows her left knee's flexion angle exhibiting neuro-atypicalmovement. Graph 1000 b shows her knee kinematics with FES applied.Kinematic signal 1001 b of the graph 1000 b shows her right knee'sflexion angle exhibiting neurotypical movement. Kinematic signal 1002bof the graph 1000 b shows her left knee's flexion angle augmented by FESand exhibiting movement that more closely aligns with the neurotypicalkinematic signal 100 lb than with the neuro-atypical kinematic signal1002 a.

FIG. 11 shows an experimental finding 1100 of the movement predictionaccuracy of the symptom intervention assembly. Sensors of the symptomintervention assembly measured EMG signals representing the user'sintention to move as the user took a step forward (“forward”), forwarddiagonally (“diagonal_forward”), sideway (“side”), backward diagonally(“diagonal_back”), backward (“back”), forward twice (“forward_double”),forward diagonally twice (“diagonal_forward_double”), sideway twice(“side_double”), backward diagonally twice (“diagonal_back_double”), andbackward twice (“back_double”). The confusion matrix shows a matrix ofprediction accuracy values. The accuracy of a predicted movement againstthe true movement are listed in the cells of the confusion matrix. Forexample, the symptom intervention assembly accurately predicted a stepforward diagonally twice with 96% accuracy, where the remaining 4% ofthe predictions were incorrectly predicted as a step forward twice. Theshading in the confusion matrix corresponds to the level of accuracy,where darker shading indicates higher accuracy. The experimental finding1100 shows that the symptom intervention assembly can predict movementsfrom measured EMG signals with high accuracy.

FIG. 12 shows experimental findings 1200 and 1210 of the impact offatigue upon muscle electroactivity. The symptom intervention assemblycan monitor a user's EMG signals and determine a level of fatigue, whichcan be used to predict events (e.g., slowed or shuffling gait) resultingfrom the fatigue. The finding 1200 shows a frequency response of EMGsignals measured at a user of the symptom intervention assembly when theuser was rested and when the user was fatigued. A rested muscle has ahigh frequency response than a fatigued muscle. In particular, fasttwitch muscles can be the first to tire, and EMG signals measured atthose muscles shows a lower frequency content when those muscles becomefatigued. The symptom intervention assembly can combine measuredkinematics and EMG signals to perform event prediction. Further, EMGsignals and fatigue may be metrics for determining if the user isexperiencing an “on” or “off” period of a chemical stimulus.

Additional Considerations

The foregoing description of the embodiments has been presented for thepurpose of illustration; it is not intended to be exhaustive or to limitthe patent rights to the precise forms disclosed. Persons skilled in therelevant art can appreciate that many modifications and variations arepossible in light of the above disclosure.

Some portions of the preceding detailed descriptions have been presentedin terms of algorithms and symbolic representations of operations ondata bits within a computer memory. These operations, while describedfunctionally, computationally, or logically, are understood to beimplemented by computer programs or equivalent electrical circuits,microcode, or the like. Furthermore, it has also proven convenient attimes, to refer to these arrangements of operations as modules, withoutloss of generality. The described operations and their associatedmodules may be embodied in software, firmware, hardware, or anycombinations thereof

The present disclosure also relates to an apparatus for performing theoperations herein. This apparatus may be specially constructed for theintended purposes, or it may include a computer selectively activated orreconfigured by a computer program stored in the computer. Such acomputer program may be stored in a computer readable storage medium,such as, but not limited to, any type of disk including CD-ROMs andmagnetic-optical disks, read-only memories (ROMs), random accessmemories (RAMs), EPROMs, EEPROMs, magnetic or optical cards, or any typeof media suitable for storing electronic instructions, each coupled to acomputer system bus.

In addition, the present disclosure is not described with reference toany particular programming language. It will be appreciated that avariety of programming languages may be used to implement the teachingsof the disclosure as described herein. Embodiments may also relate to anapparatus for performing the operations herein. This apparatus may bespecially constructed for the required purposes, and/or it may comprisea general-purpose computing device selectively activated or reconfiguredby a computer program stored in the computer. Such a computer programmay be stored in a non-transitory, tangible computer readable storagemedium, or any type of media suitable for storing electronicinstructions, which may be coupled to a computer system bus.Furthermore, any computing systems referred to in the specification mayinclude a single processor or may be architectures employing multipleprocessor designs for increased computing capability.

As used herein any reference to “one embodiment” or “an embodiment”means that a particular element, feature, structure, or characteristicdescribed in connection with the embodiment is included in at least oneembodiment. The appearances of the phrase “in one embodiment” in variousplaces in the specification are not necessarily all referring to thesame embodiment. Where values are described as “approximate” or“substantially” (or their derivatives), such values should be construedas accurate +/−10% unless another meaning is apparent from the context.From example, “approximately ten” should be understood to mean “in arange from nine to eleven.” As used herein, the terms “comprises,”“comprising,” “includes,” “including,” “has,” “having” or any othervariation thereof, are intended to cover a non-exclusive inclusion. Forexample, a process, method, article, or apparatus that comprises a listof elements is not necessarily limited to only those elements but mayinclude other elements not expressly listed or inherent to such process,method, article, or apparatus. Further, unless expressly stated to thecontrary, “or” refers to an inclusive or and not to an exclusive or. Forexample, a condition A or B is satisfied by any one of the following: Ais true (or present) and B is false (or not present), A is false (or notpresent) and B is true (or present), and both A and B are true (orpresent). In addition, use of the “a” or “an” are employed to describeelements and components of the embodiments herein. This is done merelyfor convenience and to give a general sense of the invention. Thisdescription should be read to include one or at least one and thesingular also includes the plural unless it is obvious that it is meantotherwise.

Finally, the language used in the specification has been principallyselected for readability and instructional purposes, and it may not havebeen selected to delineate or circumscribe the patent rights. It istherefore intended that the scope of the patent rights be limited not bythis detailed description, but rather by any claims that issue on anapplication based hereon. Accordingly, the disclosure of the embodimentsis intended to be illustrative, but not limiting, of the scope of thepatent rights, which is set forth in the following claims.

What is claimed is:
 1. A method comprising: identifying a chemicalstimulus administered to a user to treat a physical condition of a user,wherein an upcoming administration of the chemical stimulus ischaracterized by at least one of a dose and a time to administer thechemical stimulus; monitoring a plurality of movement signalsrepresentative of movement of the user; determining, using amachine-learned model configured to identify an onset of a symptom ofthe physical condition based on the monitored plurality of movementsignals, whether to modify the upcoming administration of the chemicalstimulus; and in response to determining to modify the upcomingadministration of the chemical stimulus: determining a modification tothe dose or the time associated with the upcoming administration of thechemical stimulus; and applying the chemical stimulus to the user basedon the determined modification.
 2. The method of claim 1, furthercomprising: receiving historical activity data collected from aplurality of sensors configured to monitor a given user's activity data,the historical activity data including at least one of historicalmovement signals, hormone activity, a previous administration of thechemical stimulus, a heart rate, or a respiration rate; labeling thehistorical activity data with a given symptom label representative of acorresponding symptom characterized by the historical activity data;creating a first training set based on the labeled historical activitydata; and training the machine-learned model using the first trainingset.
 3. The method of claim 2, wherein the received historical activitydata is collected from sensors monitoring a plurality of users havingthe physical condition, and further comprising: labeling the monitoredplurality of movement signals with a symptom label representative of thesymptom characterized by the monitored plurality of movement signals;creating a second training set using the labeled plurality of movementsignals; and retraining the machine-learned model using the secondtraining set such that the machine-learned model is customized tomotions of the user.
 4. The method of claim 2, further comprising:receiving feedback of the determined modification indicating a measureof approval that the user has with the determined modification;modifying an association between the identified onset of the symptom ofthe physical condition and the monitored plurality of movement signals;and retraining the machine-learned model using the modified association.5. The method of claim 1, further comprising monitoring hormone activityof the user using a plurality of sensors configured to measure at leastone of a level of a hormone or a level of a biomolecule regulated by thehormone, wherein the machine-learned model is configured to identify theonset of the symptom of the physical condition further based on themonitored hormone activity.
 6. The method of claim 1, whereindetermining, using the machine-learned model, whether to modify theupcoming administration of the chemical stimulus comprises: generating afeature vector representative of the monitored plurality of movementsignals and one or more of a hormone activity of the user, a previousadministration of the chemical stimulus, and motor intent data of theuser; applying the machine-learned model to the feature vector, whereinmachine-learned model identifies the onset of the symptom with aconfidence score as being associated with the feature vector; and inresponse to the confidence score exceeding a threshold confidence,determining to modify the upcoming administration of the chemicalstimulus.
 7. The method of claim 1, further comprising: determining an“on” time duration of a previous administration of the chemicalstimulus, the “on” time duration starting at a first time to administerthe chemical stimulus and ending at an occurrence of the symptom afterthe first time to administer the chemical stimulus, the first occurrenceof the symptom identified using the machine-learned model; determiningan “off” time duration of the previous administration of the chemicalstimulus, the “off” time duration starting at the first occurrence ofthe symptom and ending at a second time to administer the chemicalstimulus after the first time; and wherein determining whether to modifythe upcoming administration of the chemical stimulus comprises: inresponse to determining that the “off” time duration is greater than the“on” time duration, determining to modify the upcoming administration.8. The method of claim 1, further comprising: causing the client deviceto render a graphical user interface (GUI) comprising user input fieldsto approve or reject the determined modification; and in response toreceiving a user input indicating that the determined modification isapproved, modifying the dose or the time associated with the upcomingadministration of the chemical stimulus.
 9. The method of claim 1,wherein the plurality of movement signals is a first plurality ofmovement signals, further comprising: measuring a second plurality ofmovement signals at a first joint of the user; measuring a thirdplurality of movement signals at a second joint of the user, the secondjoint symmetric about the sagittal plane to the first joint; determininga first kinematic metric score based on a comparison of the secondplurality of movement signals to the third plurality of movementsignals, the first kinematic metric score indicative of a measure ofsymmetry of motion about the sagittal plane; generating a baselinemovement profile of the first joint using historical movement signalscollected at the first joint; and determining a second kinematic metricscore based on a comparison of the second plurality of movement signalsto the baseline movement profile, the second kinematic metric scoreindicative of a measure of a variance from an expected movement, whereinthe machine-learned model is configured to identify the onset of thesymptom of the physical condition further based on at least one of thefirst kinematic metric score or the second kinematic metric score. 10.The method of claim 1, further comprising: determining a movementfrequency response of the plurality of movement signals, wherein themachine-learned model is configured to identify the onset of the symptomof the physical condition further based on the movement frequencyresponse.
 11. The method of claim 1, wherein the plurality of movementsignals is a first plurality of movement signals, further comprising:measuring a second plurality of movement signals at a muscle group of afoot, a shank, or a thigh of the user, the second plurality of movementsignals representative of a phase in a gait cycle; creating a baselinegait profile using historical movement signals measured at the musclegroup; and determining a gait report score based on a comparison of thesecond plurality of movement signals to the baseline gait profile,wherein the machine-learned model is configured to identify the onset ofthe symptom of the physical condition further based on the gait reportscore.
 12. The method of claim 1, wherein the plurality of movementsignals is a first plurality of movement signals, further comprising:monitoring a second plurality of movement signals representative of asymptom-affected movement of the user; and comparing the secondplurality of movement signals to a symptom profile, wherein the symptomprofile is created using historical movement data representative ofmovement while a given user is experiencing the symptom withoutassistance from chemical stimulus, wherein determining the modificationto the dose or the time associated with the upcoming administration ofthe chemical stimulus is based on the comparison of the second pluralityof movement signals to the symptom profile.
 13. The method of claim 1,further comprising: receiving a plurality of images from a camera,wherein the user is depicted in the plurality of images; and determininga change in user posture depicted in the plurality of images, whereinthe machine-learned model is configured to identify the onset of thesymptom of the physical condition further based on the change in userposture.
 14. The method of claim 1, further comprising: monitoring motorintent data of the user, the motor intent data includingelectromyography (EMG) signals; and determining a frequency response ofthe motor intent data, the frequency response indicative of an energy ofmuscle activity of the user; determining a measure of fatigue based on acomparison of the frequency response and a rested frequency responseprofile determined using historical EMG signals, wherein themachine-learned model is configured to identify the onset of the symptomof the physical condition further based on the measure of fatigue. 15.The method of claim 1, further comprising, in response to determining tomodify the upcoming administration of the chemical stimulus, providing abiofeedback to the user, the biofeedback including one or more of asensory cue to promote a neurotypical movement in the user.
 16. Themethod of claim 1, wherein the physical condition is Parkinson's diseaseand wherein the symptom is one of a gait freeze or a tremor.
 17. Themethod of claim 1, wherein the chemical stimulus is one of levodopa,carbidopa, or baclofen.
 18. The method of claim 1, wherein the time toadminister the chemical stimulus is an administration time, furthercomprising: identify a stimulus metabolism period indicating a timeperiod between the intake of the chemical stimulus and a peak efficacyof the chemical stimulus, wherein determining the modification to theadministration time comprises: determining a time at which an “off” timeduration of the chemical stimulus will begin; and updating theadministration time to be earlier, by the stimulus metabolism period,than the time at which an “off” time duration of the chemical stimuluswill begin.
 19. A system comprising a non-transitory computer-readablestorage medium storing instructions for execution and a hardwareprocessor configured to execute the instructions, the instructions, whenexecuted, cause the hardware processor to perform steps comprising:identifying a chemical stimulus administered to a user to treat aphysical condition of a user, wherein an upcoming administration of thechemical stimulus is characterized by at least one of a dose and a timeto administer the chemical stimulus; monitoring a plurality of movementsignals representative of movement of the user; determining, using amachine-learned model configured to identify an onset of a symptom ofthe physical condition based on the monitored plurality of movementsignals, whether to modify the upcoming administration of the chemicalstimulus; and in response to determining to modify the upcomingadministration of the chemical stimulus: determining a modification tothe dose or the time associated with the upcoming administration of thechemical stimulus; and transmitting the determined modification to aclient device of the user.
 20. A non-transitory computer readablestorage medium storing executable instructions that, when executed byone or more processors, cause the one or more processors to performsteps comprising: identifying a chemical stimulus administered to a userto treat a physical condition of a user, wherein an upcomingadministration of the chemical stimulus is characterized by at least oneof a dose and a time to administer the chemical stimulus; monitoring aplurality of movement signals representative of movement of the user;determining, using a machine-learned model configured to identify anonset of a symptom of the physical condition based on the monitoredplurality of movement signals, whether to modify the upcomingadministration of the chemical stimulus; and in response to determiningto modify the upcoming administration of the chemical stimulus:determining a modification to the dose or the time associated with theupcoming administration of the chemical stimulus; and transmitting thedetermined modification to a client device of the user.